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1015-49 Chronic Therapy with the Acorn Cardiac Support Device 
Normalizes mRNA Gene Expression of Integrin-�5 in 
Left Ventricular Myocardium of Dogs with Heart Failure
Sharad Rastogi, Sudhish Mishra, Ramesh C. Gupta, Makato Imai, Hani N. Sabbah, 
Henry Ford Health System, Detroit, MI
Background: In heart failure (HF), LV dilation results in increased LV mechanical wall 
stress with subsequent activation of intrinsic cardiac “stretch” receptors among which 
the integrin family of transmembrane proteins are leading candidates. Activation of 
integrin receptors results in downstream activation of p21 ras and p38 mitogen activated 
protein kinase (MAPK); the latter are “stretch” response proteins directly implicated in 
cardiomyocyte hypertrophy. We previously showed that long-term therapy with the Acorn 
Cardiac Support Device (CSD), a preformed polyester device surgically placed over 
the cardiac ventricles, reduces LV mechanical wall stress and down-regulates “stretch” 
response proteins that include p21 ras and p38α/β MAPK. Consistent with these ﬁndings, 
therapy with the CSD was shown to markedly attenuate maladaptive cardiomyocyte 
hypertrophy. In this study we examined the effects of long-term (3 months) CSD therapy 
on mRNA gene expression for intergrin-α5, a dominant member of the integrin family.
Methods: The CSD was implanted in 6 dogs with coronary microembolization-induced 
HF (LV ejection fraction <35 %). Six untreated HF dogs served as concurrent controls. LV 
tissue from all 12 HF dogs and from 6 normal (NL) dogs was used to extract RNA. mRNA 
expression for intergrin-α5 was measured using reverse transcriptase polymerase chain 
reaction (RT-PCR) and bands obtained after ethidium bromide gel electrophoresis were 
quantiﬁed in densitometeric units (du). 
Results: mRNA gene expression for intergrin-α5 increased signiﬁcantly in untreated HF 
controls compared to NL (34.6 ± 1.1 vs. 24.1 ± 0.9 du, p<0.05). Long-term therapy with 
the CSD returned mRNA gene expression of intergrin-α5 to near NL levels (26.6± 1.1 du, 
p<0.05 vs. untreated HF controls). 
Conclusions: In LV myocardium of dogs with chronic HF, mRNA gene expression for 
intergrin-α5 is increased. Chronic CSD therapy reduces mRNA expression of intergrin-α5 
to near normal levels. This normalization of a key integrin can explain the downregulation 
of stretch response proteins and the subsequent attenuation of cardiomyocyte hypertrophy 
previously reported in dogs with HF following long-term CSD therapy.
1015-50 Transluminal Endovascular Graft Placement with 
INOUE Stent Graft for Thoracic Aortic Aneurysms and 
Dissections.
Keita Odashiro, Yasuo Komura, Hitoshi Yasumoto, Hideyuki Nosaka, Masakiyo 
Nobuyoshi, Takeshi Kimura, Kanji Inoue, Kyoto University, Kyoto, Japan, Takeda 
Hospital, Kyoto, Japan
Background: Transluminal Endovascular Graft Placement (TEGP) has limitation in 
managing severe bend or side branches of the thoracic aortic lesions. The feasibility and 
efﬁcacy of TEGP with Inoue stent graft(SG) for treatment of thoracic aortic aneurysms 
and dissections was investigated. 
Methods: From Aug.1997 to Aug. 2004, we performed TEGP with Inoue SG in 59 patients 
(pts.) and 59 cases (44 men, mean age 71 years). Thirty ﬁve pts.(74%) were very high risk 
for open repair or good candidates for TEGP. The cases consist of 1 ascending, 23 arch, 
18 descending aneurysms, 17 aortic dissections. Twentytwo of the cases had straight, 21 
had single branched, 8 had dual branched, 8 had triple branched grafts.
Results: In all cases but one, SGs were implanted successfully to the intended sites. 
There was only one early death because of cerebral infarction in thrombus-rich distal arch 
aneurysm case without using ﬁlter. The other major complications were 2 major stroke, 
3 minor stroke, 1 supra-mesentric artery embolism and 2 paraparesis. After Oct. 2001, 
there were no early deaths and major embolism by using detachable or retrievable ﬁlters 
and reduction of sheath size. During follow-up period (mean 35 months, range 1 to 73), 
there were no aneurysm-related deaths. Two dissecting cases with persistent endoleaks 
needed re-TEGP after 6 months and 3 years . One distal arch aneurysm patient had late 
type I endoleak after 3 years and underwent surgical repair. 
Conclusions: Inoue SG can be used in many types of thoracic aortic aneurysms 
and dissections involving major branches of aortic arch or having severe bend and is 
especially useful for high risk pts.
1015-51 Acute and Long Term Outcomes of Percutaneous 
Coronary Intervention Prior to Aortic Root Replacement
Mark A. Meier, G. Michael Deeb, Stanley Chetcuti, Mauro Moscucci, University of 
Michigan, Ann Arbor, MI
Background: Patients requiring aortic valve replacement (AVR) often have concomitant 
coronary artery disease requiring revascularization. Simultaneous coronary artery bypass 
grafting (CABG) has been the standard of care in these patients. The clinical implications 
of a strategy of preoperative percutaneous coronary intervention (PCI) followed by AVR 
are unknown.
Methods: After the development of a strategy of preoperative PCI, all patients who 
underwent a bioprosthetic AVR in addition to coronary revascularization were separated 
into 2 groups: group A included patients revascularized surgically at the time of AVR, while 
group B included patients who underwent PCI in preparation for AVR. Clinical end-points 
included 90-day and 1-year mortality and major adverse cardiovascular events (MACE) 
deﬁned as death, repeat revascularization and admission for acute coronary syndromes.
Results: When compared with group A (n=114), patients in group B (n=20) were more 
likely to be female (p=0.008) and had more comorbidities including prior cardiothoracic 
surgery (p<0.001), diabetes (p=0.02), and pulmonary hypertension (p<0.001). Total 
cardiopulmonary bypass duration was signiﬁcantly shorter in group B patients (166.4±55.1 
vs. 202.74±40, p<0.001). The 2 groups were similar with respect to 90 day and 1 year 
mortality and MACE (Table).
Conclusions: PCI prior to bioprosthetic aortic valve replacement is an attractive 
alternative to surgical revascularization in patients with multiple comorbidities.
CABG + AVR
(n=114) PCI + AVR(n=20)
p
Age 68.8±10.1 69.9±8.3 0.66
Gender (% women) 27 60 0.008
Creatinine >1.5 mg/dl (%) 18 25 0.53
Prior Cardio Thoracic Surgery (%) 8 40 0.0006
Diabetes (%) 20 45 0.02
Ejection Fraction <55% (%) 28 45 0.19
Pulmonary Hypertention (%) 2 25 0.008
Peripheral Vascular Disease (%) 12 30 0.08
Clinical Outcomes
90 day mortality (%) 4 5 1.0
90 day MACE (%) 4 5 1.0
1 year mortality (%) 9 6 1.0
1 year MACE (%) 9 11 0.67
1015-52 Modiﬁed Maze Procedure Is An Excellent Treatment Of 
Atrial Fibrillation In Patients Undergoing Mitral Valve 
Surgery
Anil Gehi, Sacha P. Salzberg, David H. Adams, Farzan Filsouﬁ, Mount Sinai Medical 
Center, New York, NY
Background: The interest in surgery for atrial ﬁbrillation (AF) has increased over the last 
few years, especially with the availability of new technologies allowing the maze procedure 
to be undertaken without signiﬁcant increase in operative complexity. We report our 
experience using two different energy sources (radio-frequency (RF) or cryothermia).
Methods: From January 2002 to August 2004, 73 patients (32M/41F, mean age 64 years 
(range: 44-94), mean EF 50%, mean LA and RA 36 and 25 cm2) underwent a left atrial 
Maze procedure for paroxysmal or chronic AF (24 RF ablation followed by 49 cryothermic 
procedures), at the same time as mitral valve surgery (repair (n=63), replacement (n=9)). 
Concomitant procedures were tricuspid valve surgery (n=23), aortic valve surgery 
(n=7), and CABG (n=15). 61%(45/74) were in AF at the time of surgery. Lesion sets 
consisted of pulmonary vein isolation, with a connecting lesion to the mitral annulus. We 
retrospectively reviewed medical charts and assessed current outcomes (>3 months) by 
patient follow-up.
Results: Follow-up was 90% complete after a mean follow-up of 359 days (114-902). 
Operative mortality was 1.4% (n=1); one year actuarial survival was 96%(70%CI: 93-99). 
One-year freedom from AF was 82% (70%CI: 77-87). A pacemaker was required in 8% of 
patients (sick sinus syndrome). No complications were attributable to the Maze procedure. 
In univariate analysis, enlarged right atrial size and Carpentier’s Type IIIa dysfunction 
were predictors of maze failure. There was no difference in outcomes between the two 
different energy sources used.
Conclusions: The modiﬁed Maze procedure is an effective therapy for AF in patients 
undergoing mitral valve surgery. It can be applied with no apparent increased risks, with 
excellent one-year efﬁcacy, including patients with long standing AF. It has become our 
standard of care for patients with a history of AF undergoing mitral valve surgery.
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1016-45 Surgery is Superior to Thrombolytic Therapy in 
Treatment of Obstructed Mechanical Left Cardiac 
Valves: Long-term (20 years) experience
Hesham Hegazy, Walid S. Hassan, Maie Shahid, Bendehiba Latroche, Bandar 
Al-Ghamdi, Mohamed Al-Amri, Mohamed E. Fawzy, Zohair Al-Halees, King Faisal 
Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Background: Mechanical valve obstruction (MVO) remains a major complication post valve 
replacement. Several reports suggested intravenous (iv) thrombolyic therapy (TRx) as safe 
alternative to surgery but remain controversial because of high risk of complications.
Methods: Seventy consecutive patients were diagnosed with aortic or mitral MVO 
between 1983-2003. Diagnosis was established using echocardiography (TEE ± 
ﬂouroscopy if needed). All patients were immediately started on iv heparin. Unstable 
patients were either taken directly to surgery or given TRx (streptokinase or tPA). Heparin 
and/or TRx success was monitored both clinically and by echo parameters. Heparin non-
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responders were either sent for surgery or tried on TRx. Non-responders to TRx after 72 
hours were sent for surgery.
Results: Mean age was 33 years (2-60), 63% were in class III-IV and 50% in pulmonary 
edema. Reduced effective valve oriﬁce areas with or without increased gradients were 
found in 56 patients (80%) by echo ± TEE. Hemodynamic success was obtained by 
heparin alone in 7 patients. Two patients refused further treatment (died), 18 patients 
received TRx with success in 7 patients (39%) 2 of them developed stroke (successfully 
treated), fatal complications in 3 patients: 2 with massive stroke and 1 with massive 
embolic fatal myocardial infarction, TRx failed in 8 subjects all went for surgery (1 died). 
Other 43 patients who did not receive TRx were opted for surgery: One died of myocardial 
failure and 42 survived (~98%). Seven patients were pregnant: 1 died of TRx-induced 
massive stroke; other 6 went for surgery with only one death.
Conclusion: Success rate was 39% and mortality 17% with TRx while with surgery was 
96% and 4% respectively. Therefore surgery is the treatment of choice for MVO and TRx 
should be considered only in high-risk surgical patients with low clot burden.
1016-46 Pregnancy Has No Effect On The Rate Of Structural 
Deterioration Of Bioprosthetic Valves: Long-Term 18-
Year Follow-Up Results
Walid Hassan, Fayez El Shaer, Bendehiba Latroche, Sumaya Al Helali, Hesham Hegazy, 
Maie Shahid, Zohair Al Halees, King Faisal Specialist Hospital and Research Centre, 
Riyadh, Saudi Arabia
Objectives: The aim of this study is to determine the long-term effect of repeat 
pregnancies on the rate of structural deterioration of bioprosthetic cardiac valves (BPV).
Background: BPV are recommended for female patients in childbearing age to avoid 
anticoagulation hazard. Several previous reports suggest that pregnancy accelerates 
BPV degeneration; however, few data are available on long-term follow-up.
Methods: Eighty ﬁve female patients in child bearing age who underwent BPV 
replacement from 1986 to 2000 were divided into two groups: group P (49 patients) who 
got pregnant once or more (total 114 pregnancies) and group NP (36 patients) never got 
pregnant after BPV implantation. Both groups were comparable (mean age 25 ± 6 and 27 
± 7 years). Clinical and echocardiographic data were obtained annually for all subjects; 
mean follow-up 9 ± 4.8 years (ranged from 4.6 - 18.4 years). Group P had 59 BPV (68% 
mitral) and 45 in NP group (60% mitral). Majority of BPV were Hancock II. The endpoint 
was freedom from redo valve replacement for structural valve degeneration (SVD).
Results: Test of freedom from redo surgery for SVD in both groups using Cox regression 
analysis demonstrated no signiﬁcant differences between P and NP groups (RR - 1.8, 
95% CI = 0.761 - 4.256, p = 0.18). Further analysis was performed to test for potential 
effect of increased number of pregnancies on the duration to redo surgery among P group 
and there was no effect.
Conclusion: Long-term follow-up (18 years) of patients with BPV and repeated 
pregnancies did not demonstrate any pregnancy- related accelerated degeneration of 
the BPV.
1016-47 Perioperative Bridging Therapy With Unfractionated 
Heparin or Low-Molecular-Weight Heparin in Patients 
With Mechanical Heart Valves on Long-Term Oral 
Anticoagulants: Results From the REGIMEN Registry
Alex C. Spyropoulos, Andrew S. Dunn, A. Graham G Turpie, Scott Kaatz, John 
Spandorfer, James Douketis, Alan Jacobson, Floyd J. Frost, for the REGIMEN 
Investigators, Lovelace Medical Center, Albuquerque, NM
Introduction: Patients with mechanical heart valves (MHV) are at increased risk of 
thromboembolism, but the optimal perioperative management with heparin bridging 
therapy during temporary interruption of long-term oral anticoagulant (OAC) therapy 
remains unclear. REGIMEN compared the efﬁcacy and safety of perioperative LMWH or 
UFH bridging therapy in these patients.
Methods: This large, prospective, multi-center registry enrolled patients ≥18 years, on 
OAC ≥3 months prior to the elective procedure, and who mostly had treatment dose 
heparin as OAC bridge for ≥2 days pre-/post-operatively. 246 patients were enrolled in 
REGIMEN with MHV as indication for OAC. Data on patient and procedure characteristics, 
and clinical adverse events up to 30 days post-procedure were collected and compared 
for UFH and LMWH.
Results: Baseline characteristics and co-morbidities were similar between groups, 
although fewer UFH patients were male. LMWH patients spent fewer days in hospital (4.3 
vs 10.4, p< 0.001) and were less likely to undergo major surgery (duration > 45 min; 35% 
vs 61%, p = 0.01). Adverse events consisted mainly of minor bleeds (Table), but included 
a cardiac valvular/mural thrombus in the UFH group and one non-thromboembolism 
related death in each group. Major bleeding rates were similar between groups.
Conclusions: The use of LMWH as a perioperative bridging therapy in selected MHV 
patients appears to be as safe and effective as UFH, and reduces hospital stay due to the 
possibility of outpatient treatment.
Table. Adverse events in MHV patients* 
UFH (n=67) LMWH (n=166) p-value
Arterial complication, major bleed, or death 6 (9%) 8 (4.8%) 0.23
Thrombotic complications 1 (1.5%) 0 (0.0%) --
Major bleed** 5 (7.5%) 7 (4.2%) 0.31
- Intraspinal bleed 0 1 (0.6%) --
Minor bleed 8 (11.9%) 30 (18.1%) 0.25
Thrombocytopenia 0 2 (1.2%) --
Death 1 (1.5%) 1 (0.6%) --
* Data missing for 13 patients.
** ≥3g/dl decrease in Hbg post-procedure; bleeds necessitating transfusion of ≥2 units of packed red blood 
cells; retroperitoneal, intraocular, intracranial and intraspinal bleeds; and any bleed resulting in new or 
prolonged hospitalization or surgical intervention. Minor bleed was deﬁned as all other bleeding events.
1016-48 How to Report Morbid Events in Patients with 
Prosthetic Heart Valves: A Prospective Study of Patients 
Presenting with Cerebral Events
Cornelia Piper, Detlef Hering, Christoph Langer, Dieter Horstkotte, Heart Center North 
Rhine-Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany
Background: According to current guidelines for reporting of morbid events after valve 
replacement (J Thorac Cardiovasc Surg 112:708), ischemic cerebral events are arbitrarily 
considered prosthesis-related emboli. Cardioembolic stroke accounts for appr. 60-80% 
of diagnosed thromboembolic complications after mechanical valve replacement. For 
prostheses associated with a high incidence of stroke, a more intensive anticoagulation 
is recommended.
Methods: We analyzed the probable etiology of stroke episodes in 89 consecutive patients 
(51 males), aged 67 ± 13 (23-81) years with mechanical prostheses in mitral (n=33), aortic 
(n=49) or mitral and aortic position (n=7) hospitalized late (> 90 days) after surgery.
Results: Onset of symptoms was 12 ± 27 (1-196) hours before admission. On admission, 
INR > 5.0 was documented in 7 and < 1.8 in 4 patients. Cranial computed tomography 
(CCT) demonstrated bleedings in 69 (77.5%), non-embolic, predominantly lacunary 
infarctions in 7, and embolic stroke in the remaining 13 patients. Bleedings were small (< 
1.5 cm) in 42 (61%) and massive in 3 patients (4.3%). In 7 of the 13 patients (53.8%) strokes 
were considered atherothrombotic, not prosthesis-related, because of multiplicity of CCT 
defects in the same supply area plus ipsilateral carotid artery stenoses and/or ulcerous 
plaque assessed by Duplex sonography. In another 4 of these patients prosthesis-related 
stroke was likely due to a so far undiagnosed prosthetic valve endocarditis. Patients with 
INR > 5.0 had ischemic stroke in 4, and bleedings in 3, patients with INR < 1.8 ischemic 
stroke in 1, and bleedings in 3 cases.
Conclusion: The majority of patients with mechanical valve prostheses presenting with 
cerebral events suffer from cerebral bleedings. The majority of ischemic strokes are not 
prosthetic valve related or represent ﬁrst manifestation of prosthetic valve endocarditis. 
INR above/below the target range does not contribute to clinical differentiation between 
haemorrhagic and ischemic/thromboembolic episodes. Increasing the intensity of INR in 
valve patients after stroke is not justiﬁed and may be detrimental. Guidelines for reporting 
morbid events after valve replacement need revision.
1016-55 Randomized Controlled Trial on the Use of Intravenous 
Amiodarone for Prophylaxis of Atrial Fibrillation in 
Patients Undergoing Cardiac Valvular Surgery
Yanick Beaulieu, André Y. Denault, Pierre Couture, Denis Roy, Mario Talajic, Eileen 
O’Meara, Pierre Pagé, Jean-Claude Tardif, Montreal Heart Institute, Montreal, PQ, Canada
Background : Atrial ﬁbrillation (AF) is an important problem after cardiac surgery 
occurring in up to 60% of patients undergoing a valvular procedure. We studied the 
perioperative use of intravenous amiodarone to prevent postop AF in a population 
speciﬁcally undergoing valvular surgery. 
Methods: 120 patients were studied in our prospective, double-blind, randomized 
controlled trial. Sixty patients received perioperative intravenous (IV) amiodarone (300 
mg bolus over 20 minutes immediately after anesthesia induction, followed by 15 mg/
kg/day IV infusion for 48 hours) and 60 patients received placebo. Holter monitoring was 
performed for 4 days starting immediately postop. Primary outcome was the occurrence 
of postop AF (deﬁned as an episode lasting more than 30 minutes or requiring urgent 
treatment). Secondary outcomes were length of hospital stay, perioperative hemodynamic 
effects, rate of pacemaker use, and postop complications. 
Results: Overall occurrence of postop AF was 49.6%. Patients in the IV amiodarone 
group had a 60% decrease in AF at 48 hours postop, while still on the IV infusion (10% 
vs 26%, p=0.0297). At day 4 postop, the group who initially received perioperative IV 
amiodarone had 50% more AF (37% vs 19%, p=0.0363). Postop onset of AF was delayed 
in the amiodarone group (3.03 vs 2.29 days). Pacemaker use was signiﬁcantly increased 
in the amiodarone group at day 1 postop (41 vs 18%, p=0.0075). There were no other 
differences in the rate of secondary outcomes. Ninety-two percent of patients were in 
sinus rhythm at discharge, with no difference between the groups. 
Conclusion: In patients undergoing cardiac valvular surgery, a strategy using IV 
amiodarone perioperatively signiﬁcantly decreases the risk of AF while patients are 
receiving the medication but is no longer effective after the infusion is terminated.
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1045-50 Acute Effects Of Restrictive Mitral Annuloplasty In 
Patients With Chronic Heart Failure
Sven A.F. Tulner, Paul Steendijk, Robert J.M. Klautz, Jeroen J. Bax, Ernst E. van der 
Wall, Robert A.E. Dion, Department of Cardiology and Cardiothoracic Surgery, Leiden, 
The Netherlands
Background: Restrictive mitral annuloplasty (RMA) restores leaﬂet coaptation in patients 
with dilated cardiomyopathy (DCM) and mitral regurgitation. The immediate effects of 
RMA on diastolic and systolic left ventricular (LV) function are unknown.
Methods: In 20 patients (DCM n=10; control CABG n=10) we measured LV systolic 
and diastolic function using the conductance catheter before and after surgery. All DCM 
patients underwent RMA (Physio ring; two ring sizes undersized), from whom 3 received 
additional CABG. All patients underwent transesophageal echocardiographic valvular 
evaluation.
Results: All patients were successfully weaned from bypass. RMA (ring size 25±1) 
restored leaﬂet coaptation (8.0±0.2mm) with normal pressure gradients (2.8±2.1mmHg). 
In both the control and the RMA group baseline hemodynamics and systolic function 
(end-systolic elastance, Ees) did not change signiﬁcantly pre vs. post surgery (table 
below). Note that preoperative Ees and EDP in the RMA group were respectively lower 
and higher than in the control group as expected. Diastolic relaxation (Tau) improved, 
while chamber stiffness (CS) increased, comparable in both groups.
Conclusion: RMA effectively restores mitral valve competence without signiﬁcant acute 
changes in baseline hemodynamics and LV systolic function. Changes in diastolic function 
appear largely related to cardiac arrest and cardiopulmonary bypass.
* P < .05 
RMA Control
Pre Post Pre Post
CO (L/min) 5.0±1.8 5.3±0.9 5.2±1.3 6.0±1.4
EF (%) 26±7 28±5 46±17 48±19
Ees (mmHg/mL) 0.86±0.50 0.99±1.05 1.31±1.20 1.13±0.59
EDP (mmHg) 14±6 15±5 9±2 16±7*
EDV (mL) 237±89 226±52 169±104 164±51
Tau (ms) 73±18 63±15* 64±6 52±5*
CS (1/mL) 0.027±0.035 0.055±0.085 0.016±0.014 0.038±0.016*
1045-51 Left Ventricular Repair by Realignment of the Papillary 
Muscles Improves Cardiac Function in Patients with 
Ischaemic Cardiomyopathy
Diane Barker, Unnikrishnan Nair, Dominik Schlosshan, Simon Williams, Lip-Bun Tan, 
Leeds General Inﬁrmary, Leeds, United Kingdom
Background: Left ventricular volume reduction has previously been advocated as a 
treatment for patients with a dilated left ventricle. We have devised a technique of repairing 
the dilated left ventricle by realignment of the papillary muscles. This procedure restores 
the conical shape of the heart and reduces functional mitral regurgitation. The plicated 
papillary muscles act as a dynamic anchor, opposing excessive dilatation of the ventricle. 
The technique was designed to minimise trauma to the myocardium and to preserve all 
viable tissue. 
Methods: Over a 5 year period, patients with ischaemic heart disease associated with 
dilatation of the left ventricle were offered left ventricular repair. Twenty nine patients 
(mean age 61 [range 38 - 77], 76% male, NYHA class II-IV) underwent this procedure in 
combination with CABG (median 3 grafts). Eighteen patients (mean age 60 [range: 38-
77] years, 91% male) underwent full cardiopulmonary exercise testing before and after 
surgery (mean follow up 34 [range 12 to 63] months) with measurement of peak oxygen 
consumption (peak VO2) and haemodynamic indices including peak cardiac power output 
(peak CPO).
Results: The 30 day mortality in the group was 1 (3%). A signiﬁcant improvement was 
observed in NYHA functional class (from mean 2.89 pre-op to 1.34 post-op, p<0.0001). 
Of the 18 subjects who completed exercise assessment, LVVR signiﬁcantly improved 
exercise duration (mean ± SD; from 450 ± 210 seconds to 648 ± 230 seconds, p = 0.001) 
and peak VO2 (from 18.2 ± 4.3 mls/kg/min to 19.9 ± 4.9 mls/kg/min, p = 0.01). Peak 
cardiac output improved from 10.62 L/min ± 2.4 to 12.91 ± 3.7 L/min, p = 0.01. LVVR 
signiﬁcantly improved peak CPO from 2.39 ± 0.79 W to 3.26 ± 1.08 W, p<0.001 and 
cardiac reserve from 1.39 ± 0.75 W to 2.29 ± 1.09 W, p<0.001.
Conclusion: This technique of left ventricular repair can be used as a treatment for heart 
failure in patients with ischaemic heart disease. It is a relatively simple operation and can 
be performed with low mortality. It has been observed to result in signiﬁcant improvements 
in NYHA class, exercise capacity and cardiac function. The encouraging results from this 
preliminary data suggest the need for further research into the effects of this procedure.
1045-52 Nesiritide Improves Refractory Heart Failure Following 
Cardiac Surgery
Saugato Sanyal, Hugo O. Rosero, Peter Homel, Darryl Hoffman, Loren J. Harris, Robert 
F. Tranbaugh, Beth Israel Medical Center, New York, NY
BACKGROUND: Nesiritide may help manage congestive heart failure (CHF) after 
cardiac surgery, in patients refractory to vasopressors and diuretics . Endogenous Brain 
Natriuretic Peptide(BNP) levels are high in the post-operative period and we hypothesized 
that exogenous BNP would improve hemodynamics and extubation rates. Since Nesiritide 
use in cardiac surgery patients is investigational, we used it only in patients refractory to 
conventional therapy.
METHOD: In 50 consecutive postoperative patients exhibiting CHF refractory to multiple 
medications {dobutamine (78% of pts), nitroglycerine (92% of pts), and diuretics (100% 
of pts)}; Nesiritide was added and hemodynamic parameters, arrythmia incidence, 
discontinuation rates and outcomes were compared using mixed model regression and 
generalized estimation equations.
RESULTS: The mean age was 68 ± 11(range 29 to 85) years, with 46% women and 
62% diabetics. Thirty-nine had CABG, 6 had combined CABG/valve procedures and 5 
isolated valve surgery. Preoperative ejection fraction was 41±12 % and creatinine 1.3± 
0.4 mg/dl. Nesiritide was added 2.8± 3 days after surgery. It was well tolerated with one 
discontinuation for hypotension. When compared to the pre-Nesiritide average trends, it 
signiﬁcantly decreased the pulmonary artery diastolic pressures {25.8± 2.9 to 19.2±2.8 
(mm of Hg) (p<0.001)}; oxygen requirement (% FiO2) 46.2±13.2 to 37.2±17.3 (p<0.001) 
and central venous pressure {15.5±3 to 13.4±2.9(mm of Hg) (p= 0.004)} within 8 hours 
of infusion. This was associated with decreased systemic vascular resistance {1115 ± 
232 to 1024 ± 220, (woods unit)(p = 0.038)} and increased cardiac index {2.35±0.27 to 
2.49±0.19(lts/m2)(p= 0.002)} and urine output {46.6±26.9 to 91.7±47(ml/hr) (p<0.0001)}. 
Twenty two patients could be extubated within 8 hours, reducing ventilated patients from 
78% to 44% (p<0.001). Serum creatinine did not rise signiﬁcantly.
CONCLUSION: The addition of nesiritide to this group of post-operative cardiac surgery 
patients with refractory ﬂuid overload/CHF resulted in signiﬁcant diuresis, lower ﬁlling 
pressures and improved extubation rates. It was well tolerated and deserves further 
exploration.
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1046-45 The Stress-activated Protein Kinase Pathways, C-jun 
N-terminal Kinase And P38-mitogen Activated Protein 
Kinase, Regulate Fibronectin Expression In Aortic 
Regurgitation
Sharada L. Truter, Anuj Gupta, Ethan H. Leer, Zhen Huang, Lisa L. Pitlor, Jeffrey S. 
Borer, Weill Medical College of Cornell University, New York, NY
Background: Fibronectin (FN) is abnormally expressed in myocardial extracellular matrix 
in aortic regurgitation (AR). This may alter myocyte-matrix coupling, impair contractile 
force transmission and promote heart failure (CHF). Knowledge of pathways transducing 
mechanical strain to FN expression may be useful in CHF prevention. FN promoter binds 
transcription factors c-Jun and ATF-2, which modulate gene expression. MAPK modules 
c-Jun N-terminal Kinase (JNK) and p38-Mitogen Activated Protein Kinase (p38) can 
modulate c-Jun and ATF-2 activity.
Methods: To assess these pathways in FN expression, normal (NL) and AR cardiac 
ﬁbroblasts (CF) from rabbits were cultured with and without 20µM of SP600125 or 
SB203580, speciﬁc inhibitors of JNK and p38. Total RNA and cell lysates were isolated. 
RNA was northern blotted and probed with 32P-labeled FN and GAPDH cDNA. Membranes 
were hybridized, washed and autoradiographed. Cell lysates were incubated with 32P-
γ-ATP and speciﬁc substrate for each kinase. Products were separated by PAGE and 
autoradiographed. Bands were quantitated by videodensitometry.
Results: FN gene expression (FN/GAPDH) was upregulated in AR-CF v NL-CF [1.7:1, 
p=0.02]. JNK inhibition with SP600125 downregulated FN expression in AR-CF (FN/
GAPDH+inh: FN/GAPDH-inh=0.4:1, p=0.006) and in NL-CF (0.6:1, p=0.01). p38 inhibition 
with SB203580 had a parallel effect (AR-CF: FN/GAPDH+inh: FN/GAPDH-inh=0.5:1, p=0.02; 
NL-CF: 0.8:1, p=0.03). Both inhibitors downregulated FN in AR-CF more than in NL-CF 
(p<.01). Phosphorylation of c-Jun (1.7:1,p=0.08) and ATF-2 (1.5:1,p=0.11) was greater 
in AR-CF than NL-CF. SP600125 reduced c-Jun phosphorylation in AR-CF (0.5:1) and 
NL-CF (0.7:1)(both p<0.01). SB203580 inhibited p38 in AR-CF (0.8:1,p=0.04), but had 
no effect in NL-CF (NS).
Conclusion: FN over-expression in chronic AR is transduced via JNK and p38-MAPK 
modules. Effective inhibition of these pathways may modulate CHF in AR and promote 
normal contractility after valve replacement.
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1046-46 Mechanical Strains of Chronic Aortic Regurgitation 
Induces Fibronectin Over-expression via JNK and p38-
MAPK Pathways
Sharada L. Truter, Ethan H. Leer, Lisa L. Pitlor, Jeffrey S. Borer, Weill Medical College of 
Cornell Univeristy, New York, NY
Background: We have shown in an animal model that chronic aortic regurgitation 
(AR) is associated with myocardial ﬁbrosis with hyperproduction of ﬁbronectin (FN) and 
upregulation of nuclear factors c-Jun and ATF-2, contributors to FN gene activation in 
other systems. c-Jun N-terminal kinase (JNK) activates both c-Jun and ATF-2 whereas 
p38-mitogen activated protein kinase (MAPK) activates only ATF-2. To test the hypothesis 
that the mechanical strain of AR speciﬁcally induces the JNK and p38-pathways with FN 
upregulation, we exposed normal cardiac ﬁbroblasts (CF) to AR-mimicking strains in culture 
with and without addition of JNK (SP600125) and p38-MAPK (SB203580) inhibitors and 
assessed pathway activation from phosphorylation of GST-c-Jun and GST-ATF-2.
Methods: Normal CF (n=5) were grown in triplicate on collagen-coated Flexercell plates 
and strained (10-25%, 60 cycles/min) with and without inhibitors for 24hr. Cells were lysed 
and homogenized; lysate was incubated with a buffer containing 32P-�-ATP and GST-c-Jun 
or GST-ATF-2 as substrate at 20 ºC for 30 min. Samples were separated by PAGE; gels 
were dried, exposed to X-ray ﬁlm, scanned and analyzed by videodensitometry.
Results: Compared to unstrained CF, strained CF showed increase of GST-c-Jun (1.9:1, 
p=.001) and GST-ATF-2 (1.7:1, p<.001) phosphorylation. Phosphorylation of GST-c-Jun 
and of GST-ATF-2 was lower when strained CF were exposed to SP600125 (each p<.001) 
compared to untreated; no GST-c-Jun difference was seen with SB203580 (NS), but GST-
ATF-2 tended to be lower with strain and SB203580 (p=.07).
Conclusion: The mechanical strain of AR speciﬁcally induces JNK and p38-MAPK 
pathways to mediate FN hyper-expression in CF. Effective inhibition of these pathways 
may retard ﬁbrosis and modulate CHF in AR. Additional research now must identify the 
initial mechano-cellular coupling event.
1046-47 Extracellular Matrix Remodeling in the Left Ventricle 
During the Acute Phase of Aortic Valve Regurgitation
Dominic Lachance, Eric Plante, Marie-Claude Drolet, Marie Arsenault, Jacques Couet, 
Centre de recherche de l’hopital Laval, Quebec Heart Institute, Ste-Foy, PQ, Canada
Background : Aortic valve regurgitation (AR) results in important remodelling of the left 
ventricle which can eventually lead to heart failure. The early ventricular responses to 
severe aortic regurgitation have not been thoroughly investigated. Understanding the 
early adaptations of the heart to severe aortic regurgitation may enable us to improve 
and optimize its treatment. Little is known on the early response of the extracellular matrix 
(ECM) and cardiomyocytes to severe aortic valve regurgitation.
Objectives: To evaluate extracellular matrix (ECM) remodelling and cardiomyocyte 
hypertrophy in a model of acute severe aortic regurgitation
Methods: Severe aortic valve regurgitation was created in adult male Wistar rats by 
retrograde puncture of the aortic leaﬂets under echocardiographic guidance. Animals 
were divided in 4 groups (n=10/group) as follows: #1:sham (no AR) #2: 24 hours of AR #3: 
48 hours of AR and #4: 14 days of AR before they were sacriﬁced. Hearts were harvested 
in each group for tissue analysis.
Results: Signiﬁcant left ventricular hypertrophy was evident at 14 days (increase of LV 
weight +10% vs sham, p<0,01). However, cardiomyocyte cross sectional area remained 
stable during the 14 days. There was a signiﬁcant increase in the expression of collagen 
I, ﬁbronectin and MMP2 at 24 and 48 hours of AR which tended to come back to normal 
at 14 days. The amount of ﬁbroblasts within the myocardium was increased at 48 hours 
and nearly doubled at 14 days.
Conclusions: Severe aortic valve regurgitation induced major changes in the 
extracellular matrix as early as 24 hours after AR occurs. These changes may contribute 
to the hypertrophic and dilating process the heart undergoes when submitted to aortic 
regurgitation. Pharmacological management targeting the extracellular matrix components 
in the early phase of the disease needs to be investigated and may improve LV protection 
when it is submitted to severe AR.
1046-48 Plasma Brain Natriuretic Peptide is predominantly 
Elevated in Patients with Pressure Overload induced 
Hypertrophy but not with Volume Overload induced 
Hypertrophy
Masayuki Mizuno, Katsuya Kajimoto, Dai Yumino, Nobuhisa Hagiwara, Hiroshi Kasanuki, 
Tokyo Women’s Medical University, Tokyo, Japan
Background: It is suggested that cardiotrophin-1 stimulates brain natriuretic peptide 
(BNP) secretion and is elevated in patients (pts) with aortic stenosis (AS) which involves 
in pressure overload but not in pts with aortic regurgitation (AR) which involves in volume 
overload. In this study, we evaluated whether plasma BNP in pts with pressure overload is 
elevated compared with those in pts with volume overload.
Methods: In 25 pts with AS (mean pressure gradient=64 mmHg) as model for pressure 
overload and 29 pts with severe AR as model for volume overload, we evaluated a 
relationship of plasma BNP to echocardiographic and hemodynamic variables, such 
as maximum left ventricular wall thickness (LVWT), LV ejection fraction (LVEF), LV end-
diastolic volume index/pressure (LVEDVI/LVEDP). Pts with pulmonary hypertension or 
heart failure were excluded. 
Results: LVEDVI in AR was greater than in AS (141 vs. 86ml/m2, p<0.0001) and 
LVWT in AS was greater than in AR (15 vs.12mm, p<0.0001). However, there were no 
signiﬁcant differences in LVEF and LVEDP between AS and AR. Plasma BNP in AS was 
signiﬁcantly higher than AR (237 vs. 53pg/ml, p<0.0001, Figure). Plasma BNP in all pts 
did not show signiﬁcant correlation with LVEDVI. However, plasma BNP in all pts had a 
weak correlation with LVEDP (R=0.301, p=0.029) and signiﬁcantly correlated to LVWT 
(R=0.502. p=0.0001).
Conclusions: These results suggest that plasma BNP value is predominantly associated 
with pressure overload but not with volume overload in LV. 
1046-55 Evidence of Early Activation of the Adrenergic and 
Renin-Angiotensin Systems During Severe Aortic Valve 
Regurgitation in rats.
Dominic Lachance, Eric Plante, Marie Arsenault, Jacques Couet, Centre de recherche 
de l’hopital Laval, Quebec Heart Institute, Ste-Foy, PQ, Canada
Background : Aortic valve regurgitation (AR) results in important remodelling of the left 
ventricle which can eventually lead to heart failure. Vasodilators remain the preferred 
treatment option for patients with this disease. The early ventricular response to severe 
aortic regurgitation have not been thoroughly investigated. Understanding the early 
adaptations of the heart to severe aortic regurgitation may enable us to improve and 
optimize its treatment.
Objectives: To evaluate the role of the adrenergic and renin-angiotensin systems in the 
early phases of cardiac adaptation to severe aortic valve regurgitation in an animal model 
of this valvular disease.
Methods: Severe aortic valve regurgitation was created in adult male Wistar rats by 
retrograde puncture of the aortic leaﬂets under echocardiographic guidance. Animals 
were divided in 4 groups (n=10/group) as follows: #1:sham (no AR) #2: 24 hours of AR #3: 
48 hours of AR and #4: 14 days of AR before they were sacriﬁced. Hearts were harvested 
in each group for tissue analysis.
Results: β1 adreno-receptor density was acutely decreased (-27% vs sham, p<0.05) 
after 48 hours of AR as well as their regulating proteins GRK2, Gs and Gi. These acute 
changes tended to normalize after 14 days of AR. Angiotensin II receptors AT1a and AT1b 
were strongly up-regulated (5-fold increase vs sham, p<0,01) as early as 24 hours after 
the induction of AR. This up-regulation persisted at 14 days.
Conclusions: Severe aortic valve regurgitation acutely affects both the adrenergic and renin-
angiotensin systems. These changes may contribute to the hypertrophic and dilating process 
the heart undergoes when submitted to aortic regurgitation. Pharmacological management 
targeting preferentially these two systems in the early phase of the disease need to be 
investigated and may optimally protect the left ventricle submitted to severe AR.
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1072-49 Outcomes in Women Following Coronary Artery Bypass 
Surgery: Results From the Rosetta-CABG Study.
Thao Huynh, Karen Wou, Mark Eisenberg, McGill Health University, Montreal, PQ, 
Canada, Jewish General Hospital, Montreal, PQ, Canada
Background: In this contemporary era, coronary artery bypass (CABG) is increasingly 
offered to sicker patients. It is unclear whether CABG is equally beneﬁcial in both genders, 
since women are generally older with more co-morbid diseases.
Methods and results: The ROSETTA-CABG Registry was a prospective multicenter 
study examining the use of functional testing after CABG. There were 395 patients with 
78 females (19.8%). Women were older (65.3 vs 62.2 years, p=0.02) and more likely to 
be hypertensive (78.2% vs 59.3%, p=0.002) than in men. There was also a trend for a 
higher prevalence of diabetic mellitus among women (35.9% vs 26.2%, p=0.09). More 
women required CABG for acute coronary syndromes (64.1% vs 49.2%, p=0.02). At 12-
months, the composite clinical event pre-deﬁned as death, non-fatal infarction, unstable 
angina occurred in 14.1% of the women vs 5.4% of men (p=0.01). Percutaneous coronary 
intervention (PCI) was necessary in 9.0% of the women vs 2.2% for men (p=0.008). 
However, a multivariate regression analysis failed to show an independent association of 
gender with cardiac adverse events. Conclusion: Women had signiﬁcantly more clinical 
events and required more PCI following CABG. This was probably due to older age 
and more comorbid diseases since gender was not signiﬁciant in multivariate analysis. 
However, physicians should remain particularly vigilant in managing women following 
CABG, since these patients are at increased risk for adverse cardiac outcomes.
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Clinical outcomes at 12-months after CABG 
Clinical Events Men (%)N=317
Female (%)
N=78 P-values
Death 3.5 9.0 0.045
MI 0.9 3.8 0.083
Unstable angina 0.9 2.6 NS
Composite endpoint 5.4 14.1 0.010
1072-50 Depression Predicts Mortality Following Cardiac Valve 
Surgery
P. Michael Ho, Frederick A. Masoudi, John A. Spertus, Pamela N. Peterson, A. Laurie 
Shroyer, Martin McCarthy, Jr., Frederick L. Grover, Karl E. Hammermeister, John S. 
Rumsfeld, Denver VA, Denver, CO, University of Colorado Health Sciences Center, 
Denver, CO
Background: Depression is associated with mortality in several cardiovascular populations, 
but has not been evaluated in patients undergoing cardiac valve surgery. Because 
identifying non-surgical mediators of survival is important for accurate risk adjustment and 
the development of interventions to improve outcomes of care, we evaluated the hypothesis 
that depression predicts mortality following cardiac valve surgery.
Methods: This prospective cohort study enrolled 648 patients undergoing valve surgery 
at 14 VA hospitals. A preoperative Mental Health Inventory (MHI) depression screen was 
performed in all patients and patients were classiﬁed as depressed or not depressed 
using the standard MHI standard cutoff score <52. Multivariable logistic regression was 
used to evaluate the association between depression and 6-month all-cause mortality, 
adjusting for other clinical risk variables.
Results: Overall, 29.2% (189/648) of the patients were depressed at baseline. Depressed 
patients were younger, more frequently had NYHA class III/IV symptoms, and more 
likely required emergent surgery, preoperative intravenous nitroglycerin, or intra-aortic 
balloon pump. Unadjusted 6-month mortality was 13.2% for depressed patients compared 
with 7.6% for non-depressed patients (p=0.03). In multivariable analyses, depression 
remained signiﬁcantly associated with mortality (OR 1.90; 95% CI 1.07-3.40, p=0.03). 
These ﬁndings were consistent across subgroups of patients undergoing aortic valve 
replacement, mitral valve replacement and valve replacement without CABG.
Conclusion: Preoperative depression is an independent risk factor for mortality following 
cardiac valve surgery. Depression screening should be incorporated into preoperative 
risk stratiﬁcation, and future studies are warranted to determine if a pre- or post-operative 
interventions to treat depression intervention can improve patient outcomes.
1072-51 What is the Impact of Amiodarone on Postoperative 
Outcomes? A Meta-Analysis
Efﬁe L. Gillespie, Kristen A. Perkerson, C. Michael White, Jeffrey Kluger, Craig I. Coleman, 
University of Connecticut School of Pharmacy, Storrs, CT, Hartford Hospital, Hartford, CT
Background: Postoperative atrial ﬁbrillation (POAF) can occur in up to 65% of patients 
undergoing cardiothoracic surgery (CTS). Two previous meta-analyses of amiodarone for 
POAF prevention were conducted. These meta-analyses did not include three new and 
well done clinical trials which increases the available population by 60% nor did they 
evaluate stroke or total hospital cost. A new meta-analysis would provide increased power 
to evaluate important sequelae of POAF: increased embolic stroke risk, hospital length-of-
stay (LOS) and total hospital costs. To better understand the role of amiodarone in CTS, 
we conducted a meta-analysis of the current body of evidence concerning its use in the 
prevention of POAF.
Methods: A systematic literature search through August 2004 was conducted to identify 
trials of prophylactic amiodarone in CTS. The primary outcome measure was the incidence 
of POAF. Other outcome measures included the incidence of stroke, LOS and total hospital 
costs. Studies were included if they met the following criteria: (1) randomized controlled 
trials versus placebo or routine treatment, (2) prevention of POAF after coronary artery 
bypass graft (CABG) and/or valvular surgery, (3) well described protocol of intervention, 
and (4) adequate data on treatment efﬁcacy.
Results: Twelve randomized trials of amiodarone were identiﬁed. Upon meta-analysis, 
amiodarone was found to prevent POAF with the following odds ratio (OR), 0.47 (95% CI 
0.39 to 0.57). The inﬂuence of amiodarone on stroke (n=5 studies), LOS (n=8) and total 
hospital costs (n=4) was as follows: (OR, 0.41; 95% CI 0.15 to 1.12); -0.71 days (95% CI 
-0.98 to -0.44) and $-2,629 (95% CI, -6,338 to 1,080).
Conclusions: Prophylactic amiodarone reduced patients’ risk of POAF and hospital 
LOS; however, no reduction in stroke was observed. Although total hospital costs were 
reduced by over $2,600, this was not statistically signiﬁcant given the small number of 
studies evaluating this endpoint and the tremendous variation associated with post-CTS 
cost. Additional, larger studies will be required to determine the effect of prophylactic 
amiodarone on total hospital costs.
1072-52 Minimising The Incidence Of Post-operative Atrial 
Fibrillation Following Coronary Artery Bypass 
Grafting: Is A Pericardial Window More Effective Than 
Conservative Treatment?
Aziz U. Momin, Stam Kapetanakis, David McCormack, James Potts, Jatin Desai, Kings 
College Hospital, London, United Kingdom
BACKGROUND: Post-operative atrial ﬁbrillation (AF) is common following CABG and 
the presence of pericardial ﬂuid has been implicated in this process. We investigated 
the effectiveness of a posterior pericardial window (PPW) in reducing the incidence of 
pericardial ﬂuid collection and AF following CABG.
METHODS: 108 consecutive patients undergoing CABG were prospectively studied.
Study group of 50 (mean age 65.5 yrs, 43 male) patients had a PPW with pleural chest 
drains and no mediastinal drains. The PPW was a 4cm cruciate incision made parallel 
and posterior to the left phrenic nerve. Control group of 58 (mean age 68.4yrs, 43 male) 
patients without a PPW had 1 anterior mediastinal chest drain and pleural drains as 
appropriate. All subjects underwent echocardiography by the same operator (blinded to 
treatment) 4 days post-operatively.
RESULTS: There was no statistical difference in the incidence of signiﬁcant LV dysfunction 
or left atrial dilatation between the 2 groups. In the PPW group, 3 patients (6%) had AF, 
compared to 12 patients in the control group (20.1%) post CABG (p =0.03). There were 
no signiﬁcant pericardial effusion (>1cm) in the PPW group whereas 9 patients (15.5%) in 
the control group developed signiﬁcant pericardial effusion (p=0.004).
CONCLUSIONS: A posterior pericardial window allows drainage of the mediastinum 
without a mediastinal drain. With this approach we observed a signiﬁcant reduction in 
early and late pericardial effusions and incidence of post-operative AF following CABG. 
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1073-45 Evidence from a Meta-Analysis of Randomised 
Controlled Trials Shows that Primary Prevention 
of Acute Rheumatic Fever with Antibiotics is Cost 
Effective in Developing Countries
Katharine A. Robertson, Jimmy A. Volmink, Bongani M. Mayosi, University of Cape 
Town, Cape Town, South Africa
Objective: To use the tools of systematic review and meta-analysis to quantify the 
effectiveness of antibiotic treatment for sore throat, with symptoms suggestive of group A 
streptococcal (GAS) infection, for the primary prevention of acute rheumatic fever.
Methods: Trials were identiﬁed through a systematic search of titles and abstracts found 
in the Cochrane Central Register of Controlled Trials (Cochrane Library Issue 4, 2003), 
MEDLINE (1966-2003), EMBASE (1966-2003), and the reference lists of identiﬁed 
studies. The selection criteria included randomised or quasi-randomised controlled trials 
comparing the effectiveness of antibiotics versus no antibiotics for the prevention of 
rheumatic fever in patients presenting with a sore throat, with or without conﬁrmation of 
GAS infection, and no history of rheumatic fever.
Results: Ten trials (n=7665) were eligible for inclusion in this review. All of the included 
trials were conducted during the period of 1950 and 1961 and in 8 of the 10 trials the study 
population consisted of young adult males living on United States military bases. Fixed 
effects, meta-analysis revealed an overall protective effect for the use of antibiotics against 
acute rheumatic fever of 70% (RR=0.32; 95% CI = 0.21-0.48). The absolute risk reduction 
was 1.67% with an NNT of 53. When meta-analysis was restricted to include only trials 
evaluating penicillin, a protective effect of 80% was found (Fixed effect RR=0.20, 95% 
CI=0.11-0.36) with an NNT of 60. The marginal cost of preventing one case of rheumatic 
fever by a single intramuscular injection of penicillin is approximately US$46.
Conclusion: Antibiotics appear to be effective in reducing the incidence of acute rheumatic 
fever following an episode of suspected GAS pharyngitis. This effect may be achieved at 
relatively low cost if a single intramuscular penicillin injection is administered.
1073-46 Age-Related Outcome of Percutaneous Mitral Balloon 
Valvuloplasty
Angelo Ramondo, Massimo Napodano, Giuseppe Tarantini, Chiara Fraccaro, Giambattista 
Isabella, Renato Razzolini, Sabino Iliceto, University of Padova, Padova, Italy
Background Percutaneous Mitral Balloon Valvuloplasty (PMV) is the ﬁrst line treatment in 
symptomatic mitral valve stenosis. Long-term results in large series from Europe and USA are 
less favourably compared with series involving younger patients. We report on the immediate 
and long-term results of PMV in a wide range population comparing various age.
Methods A large single-center series of 626 patients underwent PMV was prospectively 
followed up for 6.5 + 2.5 years by clinical evaluation and echo. According to age, patients were 
divided in quartiles: group-1 < 41 yo group-2 42-53 yogroup-3 54-63 yo group 4 > 63 yo
Results The echo-score and the NYHA class were signiﬁcantly lower in younger patients. 
The atrial ﬁbrillation was more common in elderly. Younger patients had less severe 
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stenosis. PMV resulted in an increase in mitral valve area from 1.09 + 0.25 cm2 to 2.27 
+ 0.62 cm2. The procedure success was not different across age. However the mean 
valve area post-procedure decreased with age. At follow-up restenosis was not different 
between groups. At follow-up a progressive numbers of events a(death, mitral valve 
surgery, redoPMV) ccurred in older patients. At multivariate analysis the age was not an 
independent predictor of events at follo-up
Conclusions The PMV may be performed with a low risk and good result in younger 
patients as well as in elderly. The age was not an independent predictor of events at 
follow-up.
baseline characteristics and outcomes 
Group 1n=163 Group 2n=163 Group 3n=142 Group 4n=158 p
NYHA, mean + sd 2.18 + 0.6 2.34 + 0.6 2.31 + 0.5 2.54 + 0.6 0.0001
AF, % 9.2 43.5 65.5 79.1 0.0001
Echoscore, mean + sd 5.96 + 1.7 6.95 + 1.9 7.02 + 1.8 7.86 + 2.1 0.0001
pre-PVM MVA, cm2 1.12 + 0.2 1.06 + 0.2 1.05 + 0.2 1.02 + 0.2 0.002
post-PVM MVA, cm2 2.43 + 0.5 2.17 + 0.5 2.05 + 0.4 1.95 + 0.4 0.0001
Success, % 96.3 95.1 93.7 93.6 0.67
Follow-up MACE, % 12.9 26.1 19.3 31.0 0.006
Restenosis, % 19.7 26.2 23.1 27.1 0.69
1073-47 Long-Term Results (Up to 14 Years) of Mitral Balloon 
Valvotomy in a Series of 468 Patients and Predictors of 
Long-Term Outcome
Mohamed Eid Fawzy, Walid Hassan, Miltiadis Stefadouros, Hesham Hegazy, Fayez 
El Shaer, Mohammed Chaudhary, King Faisal Specialist Hospital & Research Centre, 
Riyadh, Saudi Arabia
Background and Aims: The objective of this study was to assess the long-term outcome 
of mitral balloon valvotomy (MBV) and identify independent predictors of restenosis and 
event- free survival.
Methods and Results: We report the immediate and long-term clinical and 
echocardiographic results of 468 consecutive patients who had successful MBV and 
were followed-up for 0.5 - 14 (mean 5.2 ± 3.6) years. Patients were divided according to 
their mitral echo score (MES) before MBV into Group A (MES ≤ 8 ; n = 318) and Group 
B (MES > 8; n = 150). MBV resulted in an immediate increase in mitral valve area (MVA) 
from 0.9 ± 0.2 cm3 to 2.0 ± 0.3 cm3 (P < 0.0001). This increase in MVA was signiﬁcantly 
(P<0.001) larger in Group A than in Group B both immediately after MBV (2.0 ± 0.28 
cm3 vs 1.8 ± 0.24 cm3, respectively) and at follow-up (1.8 ± 0.34 cm3 vs 1.6 ± 0.36 cm3, 
respectively). Restenosis occurred in 74/468 (15.8%) patients and it was less frequent 
in Group A (9.4%) than in Group B (29.3%). Actuarial freedom from restenosis for the 
whole group at 5, 7, 10, 13, 14 years was 88 ± 1%, 84 ± 2%, 72 ± 3%, 52 ± 9%, 43 ± 
11% respectively, and was signiﬁcantly higher in Group A. Event-free survival (death, redo 
MBV, mitral valve surgery) for the whole group at 5, 7, 10, 13, 14 years was 94 ± 1%, 93 
± 1%, 89 ± 2%, 76 ± 9%, 76 ± 9% respectively, and was signiﬁcantly higher for patients in 
Group A. Cox regression analysis identiﬁed MES > 8 and post-procedure MVA < 2.0 cm2 
as strong predictors of restenosis (P < 0.0001 and < 0.001, respectively).
Conclusion: The long-term results of MBV is satisfactory, patient with low MES obtain 
better immediate and long-term results.
1073-48 Immediate and Long-term Results of Repeated Mitral 
Balloon Valvotomy for Restenosis Following Earlier 
Mitral Commissurotomy
Mohamed Eid Fawzy, Hesham Hegazy, Fayez El Shaer, Walid Hassan, Mohammed 
Shoukri, Abdelmoniem El Dali, Fadel AlFadley, King Faisal Specialist Hospital and 
Research Centre, Riyadh, Saudi Arabia
Background and Aim: There is a paucity of data on the results of mitral balloon valvotomy 
(MBV) in patients with symptomatic mitral restenosis after prior commissurotomy. The aim of this 
study is to assess the immediate and long-term results of repeated MBV in such patients.
Method: From 1989 - 2003, 557 consecutive patients underwent MBV using Inoue 
balloon technique at KFSH. Of these 52 patients (Group A) had previous commissurotomy 
4-14 years earlier. (28 patients previous MBV and 24 patients previous surgical 
commissurotomy) and 505 patients (Group B) had MBV for the ﬁrst time. Patients were 
followed-up for 0.5 - 14 year after MBV with clinical and echocardiographic examination.
Results: Good immediate results (MVA ≥ 1.5 cm2 with no MR > 2/4) were obtained in 47 
patients (90%) in Group A and 479 (94.8%) in Group B. The immediate and long-term results 
are shown in Table 1. Restenosis free survival at 5, 10, 13 years were 78 ± 6%, 40 ± 8%, 8 ± 
5% for Group A and 93 ± 1%, 76 ± 3% and 60 ± 8% for Group B respectively (P < 0.0001).
Table 1 
Parameter Group A52 pts
Group B
505 pts P Value
Age (year) 28 ± 9 31 ± 10 NS
Mitral echo score (MES) 8.3 ± 1.4 7.9 ± 1 <0.05
MVA cm2
B
I
F
0.90 ± 0.21
1.9 ±0.29*
1.5 ± 0.36*
0.9 ± 0.18
2.0 ± 0.28*
1.8 ± 0.31*
NS
NS
<0.0001
Post procedure MR
0
1
2
> 2/4
34
12 (23%)
5 (9.6%)
1 (2%)
268
184 (36%)
44 (9%)
9 (1.8%)
--
--
NS
--
Restenosis 35 (72.9%) 50 (10.2%) <0.0001
Follow-up time (year) 7.6 ± 3.8 5.1 ± 3.6 <0.0001
Legend to Table 1: B=before; I=immediate; F=follow-up; * = P<0.0001
Conclusions: This study suggests that repeat MBV is a valid treatment for symptomatic 
restenosis after ﬁrst successful procedure. It gives good results in patients with favorable 
mitral valve morphology.
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1101-49 Development of New Mitral Regurgitation following 
Coronary Artery Bypass Surgery: Frequency and Risk 
Factors For Its Development
Saida Z. Campwala, Ramesh C. Bansal, Nan Wang, Anees Razzouk, Ramdas G. Pai, 
Loma Linda University Medical Center, Loma Linda, CA
Background: Continued LV Remodeling process following CABG may alter functional mitral 
valve anatomy and potentilally result in new ischemic mitral regurgitation (IMR). However, its 
occurence and mechanism has not been studied. We studied the clinical, echocardiographic, 
EKG variables associated with development of new 3-4+ IMR post-CABG.
Methods: Data was obtained on patients undergoing CABG from 1993-2001 from the 
surgical registry, echo data base and chart review. Inclusion criteria: presence of IMR grade 
<2+ (on a 1-4 scale), on a pre-CABG echocardiogram and exclusion criteria: presence of 
3-4+ IMR or history of mitral valve surgery with CABG. Post-CABG echocardiogram was 
obtained after a mean interval of 1.9 years.
Results: Study population (n=438) characteristics: age 66+11 years, 70% male and 
LVEF 49+17%. Post-CABG new 3-4+ IMR developed in 11 (10%) of the 108 patients 
with no prior IMR, 21 of the 180 (12%) patients with pre-CABG 1+IMR, and 37 of the 
150 (25%) patients with pre-CABG 2+ IMR. Development of post-CABG 3-4+ IMR by 
univariate analysis was associated with female gender (42 vs. 27%, p=0.01), lower use 
of beta-blocker (19 vs. 35%, p=0.008), prior-CABG (30 vs. 17%, p=0.01), low LVEF (42 
vs. 50%, p=0.001), presence of pre-CABG 2+ IMR ( p= 0.0002), presence of pre-CABG 
left bundle branch block (p<0.0001), development of new wall motion abnormality in non-
anterior wall distribution (p=0.02) and higher incidence of PDA lesions not being grafted 
(p=0.001). Independent predictors of 3-4+ MR development post-CABG were: female 
gender (p=0.002), lower incidence of beta-blocker use (p=0.04), drop in LVEF post CABG 
(p=0.02), presence of pre-CABG 2+ IMR (p= 0.006), presence of pre-CABG left bundle 
branch block (p=0.0009) and signiﬁcant PDA lesion not being grafted (p=0.001).
Conclusion: 1) Moderate to severe IMR may develop de novo over a mid term follow-up 
in 10-25% of CABG patients. 2) Risk factors for the development of 3-4+ IMR include 
female gender, history of prior CABG, LBBB, poor LVEF and presence of 2+ IMR. 3) 
Having on going or new ischemia in the non-anterior walls may cause IMR progression.
1101-50 Tricuspid Regurgitation Late After Mitral Valve 
Replacement For Rheumatic Mitral Valve Disease
Jae-Youn Moon, Chi Young Shim, Jong-Won Ha, Byung-Chul Chang, Se-Joong Rim, 
Yangsoo Jang, Namsik Chung, Won-Heum Shim, Seung-Yun Cho, Sung-Soon Kim, 
Yonsei Cardiovascular Center and Cardiovascular Research Institute, Yonsei University, 
Seoul, South Korea
Background: Severe tricuspid regurgitation (TR) may develop late after mitral valve 
replacement in the absence of prosthetic mitral valve dysfunction and other causes of 
left heart failure. The aim of this study was to investigate the incidence and long-term 
prognosis of severe TR late after mitral valve surgery with or without tricuspid annuloplasty 
(TAP) for rheumatic mitral valve disease. 
Method: From 309 patients who underwent mitral valve replacement (MVR) between 
1995 and 1997 at Yonsei Cardiovascular Hospital, we selected 193 patients (52 men, 
141 female; mean age 48±11) who underwent MVR for rheumatic valvular disease (TAP 
group: 56, No TAP group: 137). The mean follow up period was 83.2± 26.4 (range 3 to 114) 
months. Primary end points were time to clinical outcomes, such as death, reoperation for 
tricuspid valve, admission due to heart failure and the development of severe TR (grade 
III~IV/IV) without left side heart failure. Secondary end points were time to death from 
any cause. Patients classiﬁed into three groups: patients with coexisting mild TR (Grade 
0, trivial, I), with moderate TR (Grade II) and with severe TR (Grade III-IV) at the time of 
initial mitral valve surgery. 
Result: Twenty-one patients (10.9%) developed clinical events [Mild TR group 6/121 
(5.0%), moderate TR group 4/33 (12.1%), severe TR group 11/33 (28.2%)] during follow up 
periods. Of theses, 3 patients died from right heart failure at 23 to 27 months after severe 
TR was diagnosed. One patient had redo-TAP, and others had medical treatments. Event 
free survival rate differed signiﬁcantly over the follow-up period between three groups 
(p=0.0001). By Cox regression analysis, initial severe TR (Hazard Ratio: 5.2, 95%CI 2.2-
12.3), old age (Hazard Ratio: 4.3, 95%CI 1.4-12.8), TAP (Hazard Ratio: 4.3, 95%CI 1.8-
10.5) were the risk factor for the development of late severe TR in MVR patients. 
Conclusion: The incidence of severe TR or right heart failure in the absence of prosthetic 
mitral valve dysfunction was 10.9% in MVR patients. Despite successful TAP, the severity 
of TR at the time of mitral valve surgery was the most important factor for prediction of 
late severe TR after operation.
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1101-51 Is the Euroscore Reliable in the Prediction of Operative 
Mortality in Valve Surgery?
Bernard Iung, Gabriel Baron, Olivier Fondard, Dan Gilon, Frank Vermeer, Eric G. 
Butchart, Agnes Cachier, Alec Vahanian, on behalf of the Euro Heart Survey on Valvular 
Heart Disease, Bichat Hospital, Paris, France
Background: Being able to estimate operative mortality is paramount in decision making. 
The Euroscore has been elaborated mostly from coronary surgery. Our aim was to identify 
the predictors of operative mortality and to evaluate the predictive value of the Euroscore 
in patients operated on for valvular heart disease in the Euro Heart Survey (EHS).
Methods: Among the 5,001 pts included in the EHS on valvular heart disease in 2001, 
1231 underwent valve surgery : 876 for single native valve disease, 185 for multiple valve 
disease, and 164 for redo surgery, data being missing for 6. An associated procedure 
was performed in 404 patients (33%). The predictors of operative mortality were identiﬁed 
using multivariate logistic models. The discriminative value of the predictive models was 
evaluated calculating the area under the ROC curves (c-index).
Results: Mean age was 64±13 years, 43% of patients were in NYHA class I or II. 
Operative (30-day) mortality was 3.7% globally: 2.9% for single native valve disease, 
6.5% for multiple valve disease, and 5.8% for redo surgery. Multivariate analysis identiﬁed 
7 predictors of operative mortality: age (p=0.0003), emergent surgery (p=0.0004), urgent 
surgery (p=0.003), renal failure (p=0.003), NYHA class (p=0.009), and neurological 
dysfunction (p=0.04). When including the Euroscore in the model, the predictors of 
operative mortality were Euroscore (p<0.0001), NYHA class (p=0.018), and multiple vs. 
single valve surgery (p=0.021).
When using the Euroscore only, the area under the ROC curve was 0.736±0.044. When 
using a model including the Euroscore, NYHA class, and multiple vs. single valve surgery, 
the area under the ROC curve was 0.761±0.038 (p=0.05 vs. Euroscore).
Conclusion: 1) Operative mortality for valvular surgery is in a low range in this 
contemporary series. 2) Operative mortality is strongly determined by baseline patient 
characteristics, in particular comorbidities, and the degree of emergency of intervention. 
3) The Euroscore achieves a satisfactory prediction of operative mortality in this population 
of patients with valve disease and this may be improved by adding NYHA class and 
multiple valve surgery.
1101-52 Meta-analysis of Survival and Angina Relief After 
Transmyocardial Revascularization
Lawrence Liao, Antonio Sarria-Santamera, Ayn Huntington, David J. Whellan, David B. 
Matchar, David F. Kong, Duke Clinical Research Institute, Durham, NC
Background: Transmyocardial laser revascularization (TMR) has been developed for the 
treatment of refractory angina in coronary disease patients not amenable to standard 
revascularization.
Methods: We performed a meta-analysis of available randomized trials to evaluate TMR’s 
effect as sole revascularization therapy on survival and angina relief (≥ 2 classes) at 12 months. 
Seven trials (1053 patients) reported survival data. For angina improvement, we included 5 
trials (937 patients). Odds ratios were calculated for each trial and combined assuming an 
empiric Bayesian random-effects model. DerSimonian and Laird’s Q statistic approximated a 
χ2 statistic to test a null hypothesis that all of the studies estimated the same true value.
Results: Overall, one year survival was not signiﬁcantly changed with TMR (odds ratio 
0.93, 95% conﬁdence interval 0.59 to 1.47, p=0.76). Angina class improvement at one 
year was signiﬁcantly better with TMR (odds ratio 0.17, 95% conﬁdence interval 0.10 
to 0.27, p < 0.0001). While no individual trial demonstrated survival beneﬁt, all 5 trials 
with angina class improvement as an endpoint reported signiﬁcant differences at one 
year. Signiﬁcant heterogeneity was not detected for the survival endpoint (χ2 = 6.98 with 6 
degrees of freedom, p = 0.32), but borderline heterogeneity existed for the angina class 
endpoint (χ2 = 9.46, with 4 degrees of freedom, p = 0.051)
Conclusion: At one year, TMR produces a signiﬁcant improvement in angina class, but 
no improvement in survival.
Survival at one year 
Study n year Odds ratio (survival) 95% CI
Aaberge 100 2000 1.60 0.42, 6.05
Allen 275 1999 1.50 0.75, 3.02
Burkhoff 182 1999 0.52 0.17, 1.61
Frazier 192 1999 0.81 0.30, 2.21
Huikeshoven 30 2003 7.92 0.06, 965.8
Jones 86 1999 1.0 0.27, 3.73
Schoﬁeld 188 1999 0.34 0.10, 1.14
Overall 1053 NA 0.93 0.59, 1.47
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1102-45 Demographic Characteristics, But Not C-Reactive Protein, 
Predict Progression of Calciﬁc Aortic Valve Disease
Gian M. Novaro, Ronnier J. Aviles, Ronit Katz, Alice M. Arnold, Mary Cushman, John S. 
Gottdiener, Bruce M. Psaty, Catherine M. Otto, Brian P. Grifﬁn, Cleveland Clinic Florida, 
Weston, FL, University of Washington, Seattle, WA
Background: Calciﬁc aortic valve disease (CAVD), deﬁned as aortic sclerosis or stenosis 
(AS), results from an active cellular process with similarities to atherosclerosis including 
inﬂammation. C-reactive protein (CRP) has been associated with atherosclerosis. Whether 
CRP is associated with the presence or progression of CAVD is not known.
Methods: In 5621 men and women ≥ 65 years of age enrolled in the Cardiovascular 
Health Study, the relation between CRP and CAVD was evaluated. On echocardiography, 
29% of subjects had aortic sclerosis and 2% AS. Subjects were followed for a mean of 
5 years with repeat echocardiography. The predictive value of CRP, demographic, and 
cardiac risk factors for the progression of CAVD was analyzed. Progression was deﬁned 
as progression from a normal aortic valve (NLAV) to aortic sclerosis or AS, or progression 
from aortic sclerosis to AS.
Results: At baseline, CRP was not correlated with CAVD (P=0.55). During follow-up, 6% 
of aortic sclerosis subjects developed AS. In multivariate logistic regression models, CRP 
was not signiﬁcantly associated with either progression of NLAV and aortic sclerosis to 
AS, or of NLAV to CAVD.
Conclusions: In this longitudinal study, progression of aortic sclerosis to AS developed 
in 6% of subjects over 5 years. Older age, male gender, and shorter height were predictors 
of progression to AS, while black race appeared protective. Baseline CRP concentration 
was not signiﬁcantly associated with baseline CAVD or CAVD progression.
Multivariate predictors of progression 
NLAV/sclerosis to AS NLAV to CAVD
OR (95% CI) OR (95% CI)
Age 1.13 (1.09-1.16) 1.03 (1.01-1.05)
Male gender 3.05 (1.76-5.27) 1.32 (1.02-1.70)
Black race 0.49 (0.25-0.95) 0.31 (0.24-0.41)
Height 0.96 (0.94-0.99) 0.99 (0.99-1.01)
LDL-c 1.01 (1.00-1.01) 1.01 (1.00-1.01)
CRP 0.85 (0.70-1.03) 0.92 (0.85-1.00)
1102-46 Are Markers of Atherosclerotic Risk Predictive of 
Native Aortic Valve Stenosis Progression? - A Large 
Retrospective Study
Craig M. Peters, Zoran Popovic, Gian Novaro, William Stewart, The Cleveland Clinic 
Foundation, Cleveland, OH
Background: Aortic stenosis is one of the most common valvular lesions. Aortic stenosis 
progression has been associated with atherosclerosis. We identiﬁed seven markers for 
atherosclerosis and tested the hypothesis that the rate of aortic stenosis progression 
would increase in those with abnormal values of those markers.
Methods: Patients who had native valve aortic stenosis and two trans-thoracic 
echocardiograms greater or equal to one year apart since 1995 at our institution were 
identiﬁed. Change in aortic valve area and mean aortic valve gradient were calculated. 
Hemoglobin A1C (HgbA1c), high sensitivity c-reactive protein (hs crp), homocysteine, 
lipoprotein a (Lp a), microalbuminuria, low density lipoprotein (LDL) and b-type natriuretic 
peptide (BNP) levels were extracted from medical records. Change in aortic valve area 
and change in mean aortic valve gradient were compared between those with normal 
atherosclerotic risk markers (HgbA1c =< 7, hs crp <3, Lp a <37mg/dL, urine albumin 
<300mg/L, homocysteine <15umol/L, LDL <120, and BNP <100pg/mL) and those with 
abnormal levels of those markers. Paired t test was used to determine signiﬁcance in 
change in aortic valve area and mean aortic valve gradient between the two groups.
Results: A total of 818 patients were identiﬁed to have native valve aortic stenosis and 
two echocardiograms equal or greater than one year apart with an average age of 69.9 
years. The average time between the two echocardiograms was 38 months with a mean 
change in aortic valve area of -0.18cm2 and average change in mean aortic valve gradient 
of 9.0mmHg. In each of the seven variables analyzed, there was no signiﬁcant difference 
in change in aortic valve area or change in mean aortic valve gradient between normal 
and abnormal values (95% conﬁdence interval). The change in aortic valve area was 
0.076 +/- 0.125cm2/year and the change in mean aortic valve gradient was 3.29 +/- 
4.97mmHg/year.
Conclusion: In this large retrospective study, native aortic valve stenosis progression 
could not be predicted by abnormalities in the seven markers of atherosclerotic risk. The 
rate of progression of aortic stenosis per year was slightly less than progression data 
from other studies.
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1102-47 Cellular Characteristics of Aortic Valve Degeneration. 
Endothelial Progenitor-, Dendritic- and Inﬂammatory-
Cell Markers in Degenerative Aortic Valve Stenosis and 
Explanted Bioprostheses
Dirk Skowasch, Martin Steinmetz, Stephanie Schrempf, Katarina Mikuskova, Armin Welz, 
Berndt Lüderitz, Gerhard Bauriedel, Heart Center University of Bonn, Bonn, Germany
Background - Degenerative non-rheumatic aortic valve stenosis (AS) and long-term 
failure of aortic valve bioprostheses (BP) could share common inﬂammatory-degenerative 
pathomechanisms. Since the importance of primarily circulating cell types is currently 
recognized in cardiovascular biology and disease, we assessed the presence of progenitor 
cell- and leukocyte subtype-speciﬁc markers in surgically explanted AS-valves and in BPs.
Methods and Results - High-grade stenosed AS (n=57) and BPs (n=24) were 
immunohistochemically examined for the presence and localization of endothelial progenitor 
cells (EPCs: CD34, CD133), dendritic cells (DCs: S100), macrophages (CD68) and T-
lymphocytes (CD3), supplemented by morphometric analysis. A high percentage of both 
AS and BP surgical specimens contained cells staining for CD34 (51% AS and 75% BP, 
respectively), CD133 (51%/75%), S100 (56%/79%), CD68 (53%/79%), and CD3 (51%/58%), 
with valvular ﬁbrosa as predilection site. As a key ﬁnding, the percentage of cells staining 
for EPC-, DC-, macrophage- and lymphocyte-markers was markedly increased in BPs as 
compared to AS (CD34: 18.1±25.0% vs. 5.7±13.4%; CD133: 12.4±13.2% vs. 5.6±8.5%; 
S100: 13.8±12.9% vs. 6.7±10.6%; CD68: 34.2±29.7% vs. 3.4±4.2%; CD3: 1.6±2.9% vs. 
0.9±1.8%; P<0.04). Consistently, both cell density and degree of valvular vascularization 
were signiﬁcantly higher in AS versus BP (1,379±828 vs. 592±530 cells/mm2; 13.7±8.8 
vs. 7.8±5.6 vessels/mm2; P<0.02). Non-stenosed aortic valves (n=5) and non-implanted 
bioprostheses (n=4) were negative for all markers assessed.
Conclusion - EPC-, DC-, and inﬂammatory cell markers are present on cells within 
degenerated stenosed aortic valves, and even more frequently found in stenosed aortic 
valve bioprostheses. These data point to a systemic origin of valvular cells, and thereby 
provide novel insights into mechanisms of aortic valve stenosis.
1102-48 Clinical Signiﬁcance Between Renal Dysfunction And 
Left Ventricular Dysfunction In Elderly Patients With 
Chronic Coronary Artery Disease. 
Takashi Yamada, Masashi Iwabuchi, Hiroyoshi Yokoi, Hitoshi Yasumoto, Hideyuki 
Nosaka, Masakiyo Nobuyoshi, Kokura Memorial Hospital, Kitakyushu, Japan
Background: renal function, left ventricular function and age were thought to be major 
predictive value of adverse outcome in patients with chronic coronary artery disease.
Methods: From 1986 to 1998, at a single center, we selected successive 738 patients 
who were undergoing successful elective PCI for the ﬁrst time and their serum creatinine 
was over 1.5 with their LVEF>40 (RF group:N=283) or LVEF<40 with creatinine<1.5(LV 
group:N=455). And also acute coronary syndrome cases were excluded. And of these, we 
selected 263 patients who were elder than 70(133/130 patients;RF/LV).
Results: Mean age were 75.8/75.1(RF/LV:P=0.1758).Percent male were 51.3%/48.7% 
(P=0.6965). Patients background were as followings, hypertension: 64.7%/53.8% 
(P=0.0742), diabetes: 30.8%/33.8% (P=0.6007), hyperlipidemia: 24.0%/21.5% (P=0.6965), 
current smoker: 26.3%/20.0%(P=0.2250), multivessel disease: 75.9%/79.2%(P=0.5224), 
serum creatinine:2.99/0.98(P<0.0001) and LVEF:65.8%/28.3%(P<0.0001). Five years 
freedom from death were similar in kaplan-Meier method. (logrank 0.9517) 
Conclusion: In elderly patients, left ventricular dysfunction with normal renal functon 
might equally predict long-term adverse outcome after coronary intervention compare to 
renal dysfunction without left ventricular dysfunction. 
1102-55 Effects of Statin Therapy in Aortic Stenosis Progression
Luis Moura, José Zamorano, António Ferreira, Filomena Monteiro, Francisco Rocha-
Gonçalves, Hospital Pedro Hispano and Oporto Medical School, Oporto, Portugal, 
Hospital S. Carlos and University of Madrid, Madrid, Spain
Background: Recent studies have supported the hypothesis that aortic stenosis (AS) is 
the product of an active inﬂammatory process, with similarities to atherosclerosis.
The aim of the present study was to assess prospectively the effects of statins (ST) on 
the hemodynamic progression of AS and to evaluate the impact of ST on inﬂammatory 
markers from baseline to 24 weeks.
Methods: Open-label, prospective study. 89 consecutive patients with asymptomatic 
AS (age 73±9 years; 42 men). Patients (pts) required normal LVF, peak velocity > 2,5 
m/s with an echo performed every 6 months. 44 pts (49,4%) received ST according to 
NCEP-ATPIII guidelines; 45 (50,6%) did not. Cholesterol proﬁle, hsCRP, IL-6,CD40 lig, 
NTF and BNP serum levels were obtained. 3 pts died. 7 pts needed valvular surgery and 
4 dropouts. Our ﬁnal study population included 75 pts.
Results: No differences in baseline characteristics of the 2 groups except on total 
cholesterol (T-C), LDL-C and triglyceride (TG) levels. The nonST and ST-treated pts had 
the same degree of AS at the time of ﬁrst study (1,14±0,35 vs 1,19±0,35 respectively; 
p=0,45). During a mean follow-up of 24 weeks, no signiﬁcant differences in mean gradient 
increase, LV stroke-work loss and valve resistance between groups. When compared 
to the aortic valve area (AVA), the pts treated with ST had a decrease in AVA of 0,04 
±0,16 cm2 vs 0,07±0,14cm2 for nonST (p=0,068). Neither T-C (r=-0,12, p=0,48) nor LDL-
C(r=-0,23; p=0,17) showed a signiﬁcant correlation to AS progression. The odds ratio 
of AS progression with ST treatment was 0,26 (95% conﬁdence interval, 0,1 to 0,96). 
ST reduced median hsCRP levels by 21% at 24 weeks in the ST treated pts while a 
small decrease (7%) was observed in the nonST (p=0,36). No signiﬁcant association was 
observed between change CRP levels and change in lipid proﬁle levels over time.
Conclusions: In this short-term follow-up, ST treatment is associated with slower 
progression of AS with no trend of association with cholesterol levels. The reduction 
of CRP levels provides some evidence that ST may have anti-inﬂammatory effects 
independent to lipid-lowering effects. These early observation will be further investigated 
in forthcoming studies.
ORAL CONTRIBUTIONS
816  Percutaneous Valve Procedures
Monday, March 07, 2005, 2:00 p.m.-3:30 p.m.
Orange County Convention Center, Room 414A
2:00 p.m.
816-3 The I-REVIVE Study: Mid-Term Follow-up After 
Percutaneous Aortic Valve Implantation in non-Surgical 
Patients With Calciﬁc Aortic Stenosis
Helene Eltchaninoff, Fabrice Bauer, Christophe Tron, Carla Agatiello, Deborah Nercolini, 
Alain Cribier, Charles Nicolle Hospital, Rouen, France
The I-REVIVE Trial is the ﬁrst monocentric pilot study of percutaneous heart valve (PHV) 
implantation in patients (Pts) with calciﬁc aortic stenosis. The aim of the study was to 
assess the feasibility of PHV implantation. Inclusions were restricted to compassionate 
Pts with end-stage aortic stenosis declined by 2 independent surgical teams due to 
severe comorbidities.
Methods: The PHV is an equine pericardium bioprosthesis sutured within a 23-mm 
balloon-expandable stent. The PHV is introduced percutaneously and delivered within the 
diseased native aortic valve. Results were assessed on hemodynamics: mean gradient 
(G), aortic valve area (AVA), supra-aortic angiogram at baseline and after implantation. 
2-D echocardiography (TTE) was performed before, at day 1, day 7, 1 month and every 
3 months thereafter.
Results: 16 Pts were included from august 2003 to september 2004 (6 male; mean 
age: 82+5 years), all in NYHA class IV. All Pts were in desperate condition with at least 
2 severe comorbidities. One Pt died one day before the procedure, one Pt during aortic 
predilatation and one Pt 30 mn after successfull implantation from unexplained cause. 
PHV could not be implanted in 2. Antegrade transseptal approach was used in 9 and 
retrograde in 2. Accurate PHV positioning was conﬁrmed in all. Grade 2/4 paravalvular 
leak was noted in 2 Pts and grade 3/4 in 3. Coronary arteries were patent in all. Mean G 
decreased from 45+12 to 9+3 mm Hg and AVA increased from 0.58+0.12 to 1.7+0.1cm². 
Among the 11 implanted Pts, 4 were alive at 6 months with normal PHV function. All 
deaths were none PHV related and occurred 11+5 weeks after implantation. To date, 3 
female Pts (84 to 86 years old) are alive at 8, 10 and 12 months, with return to normal life. 
TTE data at latest follow-up showed optimal PHV functionning. Mean G was 8, 12 and 9 
mm Hg respectively whereas AVA was 1.68; 1.5 and 1.67 cm² with normal left ventricular 
function and trivial aortic regurgitation.
Conclusion: This preliminary experience conﬁrms the feasibility of PHV implantation 
and demonstrates the durability of acute clinical, hemodynamic and echographic results. 
Pivotal multicentric studies will further determine the place of this promising treatment in 
non-surgical Pts.
2:15 p.m.
816-4 First Human Cases of Percutaneous Aortic Valve 
Replacement with the REVALVING™ System
Eberhard Grube, Jean-Claude Laborde, Ashok Seth, Purshotam Lal, Raoul Bonan, 
Heart Center Siegburg, Siegburg, Germany
BACKGROUND: Percutaneous aortic valve replacement (PAVR) may become an 
alternative to open heart surgery in clinical practice. To evaluate clinical safety and efﬁcacy 
of PAVR using a bovine pericardium valve, the PAVR ReValving™ system (CoreValve, 
Paris, France) First in Man implantations were conducted.
MATERIAL/METHODS: The PAVR ReValving™ system is composed of a bovine 
pericardium valve mounted on a self-expandable frame, loaded immediately before 
the procedure in a 24 Fr catheter delivery system. The catheter is advanced retrograde 
through an inferior limb arterial access under echocardiography and angiography control 
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with a short fem-fem bypass. When positioned in regard of the aortic annulus, the external 
sheath is progressively pulled-back and the self-expandable frame is placed over the 
native diseased aortic leaﬂets.
Following successful in-vitro, animal and cadaver studies, a feasibility 21 patient study 
was initiated to evaluate the ReValving™ system as an alternative to open heart surgery 
in symptomatic aortic valvular disease. Safety and efﬁcacy of the procedure are evaluated 
upon acute, 6 months and 1 year clinical and doppler-echocardiographical studies of the 
prosthetic valvular function.
RESULTS: Acute results showed successful implantation of the ReValving™ system 
with correction of the valvular disease (calciﬁed stenotic or regurgitant aortic valves), 
perfect prosthetic valve function (low gradient, no valve regurgitation), good adhesion to 
the surrounding tissues with no para-valvular leak, no impairment of mitral valve function 
or coronary ﬂow and no migration. Complete results of the human feasibility study will be 
presented at the meeting.
CONCLUSIONS: Initial clinical experience indicates that PAVR with the ReValving™ system, 
a percutaneous implanted self-expanding pericardial valve, treats efﬁciently both calciﬁed 
aortic stenosis and aortic regurgitation. The released prosthesis showed good valvular 
function indicating that the ReValving™system may be an alternative to open heart surgery.
2:30 p.m.
816-5 Histological And Ultrastructural Recipient Tissue 
Response Six And Thirteen Months Post Percutaneous 
Valve Implant In Sheep And Calves
David Paniagua, Donna Coffey, Eduardo Induni, R David Fish, Carlos Mejia, Carolyne 
Ortiz, Fred Clubb, St Luke’s Episcopal Hospital/Texas Heart Institute, Houston, 
Endoluminal Technology Research, Miami, FL
Introduction:  The histological and ultra structural changes after long term implantation 
of percutaneous heart valve are unknown. We sought to investigate these changes in a 
cohort of animal after long term implantation.
Methods:  Six sheep and three calves weighing 30 to 60 kg underwent transcatheter 
implantation of a PHV and follow for six moths (7 sheep) and 13 months (2 calves). 
Before the euthanasia, all animal were in good general condition. The thoracic aorta was 
canulated and retrograde perfusion initiated with chilled physiologic saline (30-40 mmHg). 
Once the blood has been cleared, the heart was perfused with a 2% paraformaldehyde/2% 
glutaraldehyde ﬁxative (Karnovsky’s ﬁxative). After ﬁxation, the specimen was dehydrated 
with graded ethyl alcohol. Once absolute alcohol concentration was reached, the 
specimen was dried at room air or in a vacuum desiccator. The specimen was mounted 
on an aluminum stub. The specimen was then placed in a LVSEM (JSM-5900LV) and 
examined under low vacuum. The valve was extracted and parafﬁn tissue block were 
sectioned for HE staining, Masson-trichrom and inmunohistochemical staining with 
antibody to factor VIII.
Results: Gross evaluation of the valve showed no evidence of tears, lacerations, clot, 
calcium deposits or pannus formation. No stent struts fractures were seen. Microscopic 
evaluation of the valve at the site of attachment to the aortic wall showed focal areas of 
ﬁbrosis that were highlighted with Masson Trichrome stain.. No signiﬁcant inﬂammation 
was seen. Immunohistochemical stains for Factor VII evidenced endothelial cell on blood 
contact surface.
SEM showed a very smooth surface with no blood product deposits, tight endothelial 
cell junction. The valve’s leaftlet free border was very smooth. All stent structures were 
covered with endothelial cells.
Conclusion:  Percutaneous heart valve implantation is follow by a favorable recipient 
tissue response with complete endothelial coverage of all blood contact surfaces, ﬁbrosis of 
attachment areas and no evidence of stent fractures, laceration, blood product deposits.
2:45 p.m.
816-6 The Coronary Sinus is a Potential Target for 
Percutaneous Mitral Valve Repair as it Dilates and 
is Outwardly Displaced in Patients With Mitral 
Regurgitation
Michael S. Lee, Atman Shah, Ninh Dang, Don Bobo, Daniel Berman, John Friedman, 
Sepehr Fariabi, Joseph Aragon, Raj Makkar, Cedars-Sinai Medical Center, UCLA 
School of Medicine, Los Angeles, CA
Background: Although surgery is the current standard for the treatment of mitral 
regurgitation (MR), percutaneous intervention of the coronary sinus (CS) is being 
considered for the treatment of MR as it encompasses the mitral annulus. We sought to 
determine if the CS is dilated and outwardly displaced in patients with MR.
Methods: We studied 57 patients who were referred for biventricular pacemaker 
implantation and underwent coronary venography. MR was assessed by 2-D Doppler 
echocardiography. The CS and great cardiac vein (GCV) were viewed in left anterior 
oblique 30º, right anterior oblique 30º, and straight antero-posterior views. The diameter of 
the ostial and proximal CS and perimeter of the CS to GCV were assessed by quantitative 
analysis on coronary venography.
Results: Of the 57 patients who underwent coronary venography, MR was present in 
27 patients and absent in 30 patients. There were no signiﬁcant differences in baseline 
characteristics. Compared to patients without MR, the diameter of the ostial and proximal 
CS and perimeter of CS to GCV were longer in patients with MR (Table).
Conclusions: Coronary venography demonstrates that patients with MR have a dilated 
CS and outward displacement of the CS and GCV with a longer diameter of the ostial and 
proximal CS and perimeter of CS to GCV compared with patients without MR. Therefore, 
the reduction of the CS and GCV perimeter may reduce MR. This data may be pertinent in 
the development of percutaneous mitral annuloplasty devices that involve cinching the CS.
Mitral Regurgitation 
(n=27)
No Mitral Regurgitation 
(30) P value
Diameter of ostial CS (mm) 19.4 ± 3.9 16.9 ± 4.6 0.02
Diameter of proximal CS (mm) 8.2 ± 1.7 7.4 ± 2.3 0.05
Perimeter of CS to GCV (mm) 104.4 ± 15.6 86.5 ± 15.3 0.005
3:00 p.m.
816-7 Percutaneous Edge-to-Edge Mitral Valve Repair Using 
the Evalve Clip: Update of the EVEREST Phase I Clinical 
Trial
Ted Feldman, Hal S. Wasserman, Howard C. Herrmann, William A. Gray, Patrick L. 
Whitlow, Peter C. Block, Elyse Foster, Frederick St.Goar, Evanston Hospital, Evanston, IL
The Evalve Cardiovascular Valve Repair System has adapted an established surgical 
technique for treatment of mitral regurgitation (MR) to a percutaneous transseptal 
approach. The Endovascular Valve Edge-to-Edge Repair Study (EVEREST I) is a multi-
center, prospective phase I trial to evaluate the safety and feasibility of this technology. 
27 patients have been enrolled to date. Under general anesthesia and trans-esophageal 
echo guidance, the middle mitral leaﬂet scallops are grasped and coapted by a clip, 
creating a double oriﬁce valve and reducing MR. The primary endpoint is the rate of death, 
MI, tamponade, clip detachment, cardiac surgery, stroke, and septicemia at 30 days. 
Surgical candidates with moderate-severe or severe MR (grade 3+ or 4+) with symptoms 
(or asymptomatic with EF <60% or LVESD >45 mm) were included. Exclusion criteria 
included EF <30%, LVESD >55 mm, endocarditis, prior sternotomy, and rheumatic heart 
disease. Secondary endpoints include 30 day and 6 month MR.
Results: 20 patients (mean age = 68 yrs; 75% male) have undergone the procedure 
for degenerative (90%) or functional (ischemic) MR (10%) and have 30-day follow-up. 
Successful leaﬂet coaptation was obtained in all patients, and clips were implanted in 17 
Clip implantation with immediate MR reduction to ≤2+ was accomplished in 13 of these 
17 patients (76%), including 2 patients who received 2 clips. There were no procedural 
complications and only one major adverse event: a partial clip detachment in one patient 
who underwent elective valve repair. Two additional patients have undergone surgery for 
unresolved MR, with the remaining 14 patients (82%) are free from surgery. Mean device 
time fell from 204 mins in the ﬁrst 9 cases to 161 mins in the second 9 single-clip cases . 
All patients were discharged home after a mean of 1.7 days.
Conclusion: Edge-to-Edge mitral valve repair can be accomplished sucessfully using 
this percutaneous system, successfully reducing both degenerative and functional MR 
with an acceptable rate of complications.
3:15 p.m.
816-8 Impact Of Age On The Outcome Of Women With 
Coronary Artery Disease Following Percutaneous 
Coronary Intervention In The Stent Era
Sudhir Rathore, Julie Rhys, Maurice B. Buchalter, Peter H. Groves, Nick O. Gerning, 
William John Penny, University Hospital of Wales, Cardiff, United Kingdom
Background- Advanced age and female gender are both independent predictors of early 
and late mortality and adverse outcomes following angioplasty. Elderly women are at 
particular risk.Whether elderly women remain at risk after PCI in stent era has not been 
examined widely.
Methods- Prospective data was analysed in 396 consecutive female patients undergoing 
PCI during 1999-2003. Primary PCI patients were excluded.
Results- Compared to young women [< 65 yrs, median age,56], elderly women [> 65 
yrs, median age 70], were less likely to smoke [15.7% / 47.2%, p= .001]; less likely to 
have diabetes [4.1% / 8.5%, p=.05 ];and had more multivessel coronary disease [ 55.3% 
/41.7%, p= .005].Indication was elective in[61.3% /68.5%] and Emergency in[38.% 
/31.5%]. Usage of stent was high [ 88.4% /88.8% ], similar in both groups. Hypertension, 
hypercholestrolemia, previous MI, vessel’s treated, abciximab usage [ 24.6% /22.3%] and 
access site bleeding rates[ 10.6% /13.2%] were similar in both groups. Outcomes are 
shown in table 1.
Conclusions- Elderly women, undergoing PCI, have a distinct proﬁle presenting with 
more multivessel disease, less smoking and are less likely to have diabetes than younger 
women. In the stent era, procedural success, in-hospital adverse cardiac events and 
MACE at 1 year are similar in both groups. At 1 year, however elderly women are less 
likely to have ischaemia driven TVR and recurrence of angina.Outcomes in younger 
women could be improved by improving their proﬁle and usage of drug eluting stents.
Outcomes following PCI 
Variable % < 65 Yrs[N-199] >65 Yrs[N-197] P Value
Procedural success 96% 98% ns
In Hospital Mortality 0.5% 1% 0.8
Emergency CABG 3.5% 0.5% 0.2
Mortality at 1 yr 1% 1.5% 0.8
Stroke at 1 yr 1% 1.5% 0.8
Ichaemia driven TVR at 1 yr 10.1% 8.1% 0.5
MI at 1 yr 12.1% 14.2% 0.6
Recurence of angina at 1 yr[ Stable] 25.6% 17.3% 0.05
MACE[ Mortality+TVR+MI] 23.1% 25% 0.7
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1130-49 Randomized Study of Surgical Correction of Permanent 
Atrial Fibrillation
Alvaro Albrecht, Renato A. Kalil, Gustavo G. de Lima, Marcelo H. Miglioransa, Eduardo 
Tigre, Daniel Faria-Corrêa, Rogério Abrahão, Abud Homsi, Paulo L. Moreno, Paulo 
R. Prates, João Ricardo M. Sant’Anna, Ivo A. Nesralla, Institute of Cardiology of Rio 
Grande do Sul, Porto Alegre, Brazil
Background: A Surgeon faces multiple techniques to treat permanent atrial ﬁbrillation 
(AF), but there are few studies designed to compare approaches. We here analyze the 
results of a prospective, randomized study that compares Maze surgery or Isolation of 
Pulmonary Veins (IPV), with a Control group, and establish the best treatment for this 
arrhythmia.
Methods: All patients (PTS) were referred for surgery for other cardiac lesions, which was 
treated concurrently. From July 1999 to September 2003 ,ﬁfty-one PTS where randomly 
allocated to three different groups. No cryoablation or other source of energy was used. 
Cox-Maze III Surgery, and IPV, with cut and sew technique were used. The following 
variables were initially analyzed: total bypass time, aortic clamping time, sinus rhythm at 
discharge, and trans-operative and immediate post-operative complications.
Results: Mean age was 53±12,5, similar between groups, and were no difference in the 
PTS characteristics. There were two intra-hospitalar deaths, one in the Maze group and 
one in the IPV group. Treatment groups had longer bypass and crossclamp time (p<0,001). 
Follow-up of 28.4 ±14 months was similar between the groups. Group IPV achieved best 
results concerning reversion to sinus rhythm with 84.2% at hospital discharge and 88.9% 
after follow-up. In Maze group, 78.5% of sinus rhythm at discharge and 84.6% at end of 
follow-up. In Control group 87.5% with AF at discharge, and after follow-up AF in 56.3% 
of the PTS. There were no differences in the New York Heart Association Functional 
Classiﬁcation between the groups before or after follow-up (p=0.56), and Control group 
patients had more complications (p=0.017).
Conclusion: These results show that both techniques, the Maze and Isolation of 
Pulmonary Veins, have advantages over simple correction of cardiac lesions when 
associated to permanent atrial ﬁbrillation.
1130-50 Comparison Between Different Assays of Natriuretic 
Peptides (Pro-BNP and BNP) in Patients Undergoing 
Coronary Artery Bypass Graft Surgery
M Javed Ashraf, James R. Cook, James Nichols, Mara Slawsky, Baystate Medical 
Center, Springﬁeld, MA
Background: B-type natiuretic peptide (BNP) and NT-Pro B-type natiuretic peptide 
(proBNP) identify left ventricular dysfunction and congestive heart failure, but no 
comparative data exist for the 2 peptides. We evaluated BNP and proBNP in 100 patients 
undergoing elective coronary artery bypass grafting (CABG) surgery.
Methods: BNP and proBNP levels were measured prior to CABG and postoperatively 
at 3 and 24 hrs. Data were log transformed, the Spearman correlation coefﬁcient and 
Hotelling’s T-squared test to analyze baseline measures and changes over time.
Results: The mean patient age was 68+10.5 years, 27% were female, 5% had a history 
of CHF, 34% prior MI and 15% had an LVEF < .40. Baseline BNP and proBNP levels were 
positively correlated (r=0.93,p<0.001, ﬁg 1). Both levels decreased signiﬁcantly at 3 hours 
post-op and returned to levels above baseline at 24 hours (p<0.001 for both). No signiﬁcant 
difference was evident for the change in values between the two peptides at 3 or 24 hours.
Conclusions: There is a strong and signiﬁcant correlation between BNP and proBNP 
levels in patients undergoing elective CABG and both seem to respond similarly to 
operative stress.
 
1130-51 Impact of Graft Age, Remodelling, and Calciﬁcation 
to the Development of Coronary Artery Bypass 
Graft Plaque Rupture: An Intravascular Ultrasound 
Comparison of Ruptured and Non-ruptured 
Atherosclerotic Plaques in the Same and Control 
Saphenous Vein Grafts.
Jerzy Pregowski, Pawel Tyczynski, Gary Mintz, Sang-Wook Kim, Augusto Pichard, 
Adam Witkowski, Lukasz Kalinczuk, Ron Waksman, Neil Weissman, Washington 
Hospital Center, Washington, DC, Cardiovscular Research Foundation, New York, NY
Ruptured atherosclerotic plaques (RP) in saphenous vein grafts (SVGs) have not been 
described with intravascular ultrasounds (IVUS). We used IVUS to compare ruptured 
SVG plaques vs non-ruptured plaques in the same SVG (Control Plaques) vs clinically 
matched patients without ruptured SVG plaques (Control SVGs).
Methods: We identiﬁed 33 RPs in 25 SVGs in 24 patients in which we could also identify 
secondary Control Plaques. We clinically matched (age, gender, etc.) these to 33 SVG pts 
from a database of over 300 pre-intervention SVG IVUS without RP. IVUS measurements 
were performed at maximal plaque cavity site (MPC), minimal lumen area site (MLA), and 
proximal and distal references. Remodeling index (RI) was the ratio of lesion SVG area 
to mean reference. 
Results: SVGs with RP were older (13.5±4.7 vs 9.1±5.1yrs; p=0.001). There was more 
positive remodelling in RP and Control Plaques in the same SVG compared to Control 
SVGs (79% vs.75% vs.33%, respectively, p<0.001). RPs had more calcium deposits at 
the lesion site (64% vs 29% vs 36%, respectively, p=0.017). RP and control plaques in the 
same SVG were more often eccentric (maximum/minimum plaque thickness>3, 64% vs 
58%vs 36% p=0.07). Lesions in Control SVGs had smaller lumen areas. (Table).
Conclusions. Ruptured plaques occur in older SVGs. However, even within older SVGs, 
the site of plaque rupture is associated with more positive remodeling, lesion calcium, and 
lesion eccentricity which may contribute to or be markers of plaque ruptur
RP Control plaques Control SVGs P (Anova)
MLA (mm2) 4.2±2.0 5.2±2.0 3.6±1.7 0.004
Lesion SVG area (mm2) 23.6±6.7 21.8±6.3 21.8±10.0 0.7
Reference LA (mm2) 10.4± 3.5 10.4± 3.9 10.2± 5,0 1,0
Reference SVG area (mm2) 19.6 ±6.1 21.4± 5.8 23.7± 12.0 0.2
RI 1.23± 0.25 1.07 ± 0.2 0.93± 0.22 <0.001
1130-52 Pre-operative Cholesterol Levels Do Not Predict 
Structural Valve Degeneration In Patients Undergoing 
Bioprosthetic Mitral Valve Replacement
Christian Gring, Penny Houghtaling, Gian Novaro, Nicholas Smedira, Michael Banbury, 
Eric Roselli, Eugene Blackstone, Brian Grifﬁn, Cleveland Clinic Foundation, Cleveland, OH
Background: Structural valve degeneration (SVD) is a common cause of bioprosthetic 
valve failure. Studies have linked atherosclerotic risk factors with SVD. We hypothesized 
that total cholesterol (TC) levels at the time of bioprosthetic mitral valve replacement 
(MVR) would predict SVD.
Methods: We identiﬁed 1,935 patients who had an isolated bioprosthetic MVR from1975 
to 2002, and who had prospective data in our institution’s surgical database. A multivariable 
model, including patient demographics, cardiac and non-cardiac comorbidities, valve type, 
and interactions identiﬁed risk factors for SVD explant, which was the primary endpoint. 
All explants were examined, and observations were censored at the time of any explant 
or death. TC was analyzed by tertiles. HDL-C and LDL-C were noted in 773 and 640 
patients, respectively. Bootstrap analysis was used to validate the model.
Results: Mean values for patient age = 67 +/-11 years, TC=200 +/- 51 mg/dL, HDL=44 +/- 
16mg/dL, and LDL=113 +/- 40 mg/dL. Follow-up was 4.3 years, and 25% were followed >8 
years. There were 131 explants for SVD. Only younger age predicted SVD (p<0.001). In the 
unadjusted model TC, HDL, and LDL did not predict explant for SVD (log-rank p=0.2 for TC). 
Likewise, coronary disease, atherosclerotic risk factors, and creatinine were not predictive. 
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1131-45 Effects of Acute Blood Pressure Change on the Echo 
Doppler Assessment of Aortic Stenosis Severity
Stephen H. Little, Kwan L. Chan, Ian G. Burwash, University of Ottawa Heart Institute, 
Ottawa, ON, Canada
Background: Several indices have been employed to assess aortic stenosis (AS) 
severity. However, the effect of blood pressure (BP) and systemic arterial hypertension 
on the assessment and interpretation of AS severity using these indices is unknown. We 
sought to investigate the effect of arterial BP augmentation on the echo-Doppler indices 
of AS severity.
Methods: In 22 patients with valvular AS (AVA 1.15±0.32 cm2), BP was increased using 
either rhythmic handgrip exercise for 8 minutes (40% of predetermined maximum voluntary 
contraction using a calibrated dynamometer) or phenylephrine infusion. Echo-Doppler 
indices of AS severity were measured at baseline, at peak intervention and following 
recovery. AVA was derived from time velocity integrals using the continuity equation. Valve 
resistance (RES) was calculated from Doppler mean pressure gradient (ΔPmean) and the 
mean LV outﬂow tract ﬂow (Qmean), where RES =ΔPmean/Qmean x1333. % LV stroke 
work loss was derived as ΔPmean/(systolic BP + ΔPmean) x 100%. Energy loss coefﬁcient 
(ELC) was derived as (AVA x ascending aorta area)/(AVA - ascending aorta area).
Results: From baseline to intervention, BP increased from 143±14/77±9 to 181±20/92±8 
mmHg (p<0.0001 for systolic and diastolic BP, respectively) and mean BP increased from 
99±8 to 121±10 mmHg (p<0.0001); Qmean decreased from 323±67 to 306±66 ml/sec 
(p=0.02). There was no change in ΔPmax (59±21 to 60±24 mmHg, p=NS) or ΔPmean 
(32±12 to 32±14 mmHg, p=NS). In contrast, AVA decreased (1.15±0.32 to 1.09±0.33 cm2, 
p=0.02), % LVSW loss decreased (18.2 ±6 to 14.8±6%, p<0.0001) and ELC decreased 
(1.35 +/- 0.40 to 1.27 +/- 0.42 cm2, p=0.03). There was no change in RES (139±57 to 
145±71 dynes-sec/cm5 , p=NS). The change in AVA was inversely related to the change in 
mean BP on linear regression analysis (r=-0.34, p=0.025).
Conclusion: Systemic BP inﬂuences the echo-Doppler assessment of AS severity. 
Elevation in blood pressure results in the valve stenosis appearing more severe when 
assessed by AVA or the energy loss coefﬁcient and less severe when assessed by % LV 
stroke work loss. In contrast, transvalvular pressure gradient and valve resistance were 
not affected by acute changes in arterial BP.
1131-46 Rapid Cardiovascular MRI (CMR) 3D Quantitation 
of Aortic Stenosis Velocities in Comparison With 
Echocardiography: Who Is Correct?
Vikas K. Rathi, Mark Doyle, June Yamrozik, Maulik Patel, Ronald B. Williams, Diane 
A. Vido, Valerie Bress, James A. Magovern, Sunil Mankad, Robert W.W. Biederman, 
Allegheny General Hospital, Pittsburgh, PA
Introduction: Limitations of transvalvular assessments by echocardiography (Echo) exist. 
Yet, Echo remains the workhorse diagnostic modality. Phase velocity mapping (PVM) by 
CMR can rapidly and reliably acquire velocity and ﬂow data in 3D, not possible by Echo.
Hypothesis: CMR can provide similar assessment of valvar velocities in symptomatic 
aortic stenosis (AS) patients as Echo and, if discordant, determine which modality 
approached the truth.
Methods: Twenty-seven subjects (20 symptomatic AS; 7 controls) underwent blinded 
CMR (GE 1.5TCV/i) PVM analysis of AS followed by blinded Echo (Philips 5500, Andover, 
MA). CMR PVM parameters: TR 19±4ms, X,Y and Z encoding, and ofﬂine analysis of 
aortic transvalvar velocities (Avel).
Results: There was a high degree of correlation between CMR and Echo transvalvar 
metrics. Overall, 19/20 (95%) and 14/20 (70%) pts by CMR and Echo had peak Avel>4.0m/
s . Concordance for Avel>4m/s was 88%. Importantly, discordance was partially explained 
by 2/20 Echo’s having cosine theta errors >350. Nevertheless, the correlations were r= 
0.89, 0.88 and 0.74 for peak, mean velocity and peak gradient, respectively, p<0.0005 
for all. The peak and mean CMR vs. Echo Avel were: 426±153 vs. 352±213, 278.5±136.8 
vs. 251.3±114.6 cm/s, respectively. There was no difference in control gradients (5.3 vs. 
4.2 mmHg). Bland-Altman CI’s were reasonable for bias and precision. Despite this, the 
Echo Avel were consistently and proportionately lower then CMR. Importantly, since either 
technique can under but not overestimate velocity and CMR has undergone phantom 
correlations, this suggests that CMR represents velocities closer to the truth. The 
difference in Avel acquisition time was 1±2min fewer for CMR.
Conclusion: CMR has theoretic, practical, and now precision and time advantages in 
AS. Transvalvular velocities are similar and both techniques identify patients legitimate 
for AS surgery. While CMR demonstrates high correlation with Echo, it may have higher 
inherent accuracy as correlated to ﬂow phantoms. When added to its capacity as the 
‘gold standard’ for LV structure, function, mass, and thoracic aortic imaging, CMR should 
strongly be considered for assessment of AS.
1131-47 Effects of Changes in Cardiac Output and Leaﬂet 
Properties on Echocardiographic Markers of Aortic 
Valve Stiffness
Alok SINGH, Michael D. VanAuker, Katherine Rhodes, Thomas J. Koob, Joel A. Strom, 
University of South Florida, Tampa, FL
Background: Predicting the rate of progression of aortic valve stenosis has been elusive. 
The ratio of the mid-deceleration aortic valve area (AVA) to the mid-acceleration AVA 
(AVA-ratio) during ejection has been proposed to predict rapid disease progression. 
The AVA-ratio is related to valve stiffness and the instantaneous transvalvular pressure 
gradients; the latter is affected by systolic function. We investigated effects of cardiac 
output and valve stiffness on opening and closing rates and AVA-ratio. 
Methods: We studied 15 porcine valves of similar annulus size: 5 were stored in ethanol 
(E), 5 were treated with NDGA and 5 with gluteraldehyde (G) to achieve different stiffness. 
Peak pressure gradient (ΔP), AVA, and AVA-ratio were measured in a pulse duplicator at 
various ﬂow rates. 
Results: The mean AVA for E was 1.08 cm2. Compared to E, ΔP increased by 15mmHg 
with NDGA and 22 mmHg with G (both p<0.001) while AVA decreased by 0.22 cm2 and 
0.26 cm2 respectively (p≤0.001). The effect of ﬂow rate on ΔP, AVA, and AVA-ratio for all 
valves are shown in the table. Reduction in the mid-acceleration AVA caused most of 
the change in the AVA-ratio. Flow rate (p<0.001) had a greater effect on AVA-ratio than 
valve treatment (p=0.05). Mid-acceleration AVA was affected by ﬂow (p<0.002), while mid-
deceleration AVA by valve treatment (p<0.01).
Conclusions: AVA-ratio is predominantly affected by stroke volume. Increases in cardiac 
output alter the rate of valve opening, while leaﬂet properties determine the rate of closure.
Flow Rate (L/min) ΔP (mm Hg) AVA(cm2) AVA-Ratio
2.0 16 0.94 1.16
3.25 38* 0.85 1.16
4.5 55* 0.91 1.64+
5.75 73* 0.99 2.10*
*p<0.003 +p<0.05 Vs. 2.0L/Min
1131-48 Determinants of Plasma N-terminal pro B-type 
Natriuretic Peptide in Aortic Valvular Disease: 
Comparisons of Echocardiographic indexes of Volume 
and Pressure-overload
Seong-Hoon Lim, Samsung Medical Center, Seoul, South Korea
Background: The increased mechanical stress manifestated by augmented myocardial 
stretch (from volume or pressure overload) play a role in releasing of B-type natriuretic 
peptide(BNP). BNP and N-terminal proBNP(NT-proBNP) levels in patients with heart 
failure correlate with functional class, left ventricular end-diastolic pressure(LVEDP) and 
inversely correlate with ejection fraction. However, the differences of NT-proBNP levels 
in patients with aortic valvular disease due to volume-overload(aortic regurgitation, 
AR) or pressure-overload(aortic stenosis, AS) have not been identiﬁed. To identify the 
determinants of the NT-proBNP levels in patients with AR and AS, the echocardiographic 
indexes were compared to the levels of NT-proBNP between two groups.
Method: Fifty-one patients who were diagnosed as aortic valvular disease by transthoracic 
echocardiography were enrolled. (AS=21, AR=30) After TTE, NT-proBNP was measured 
within 2weeks by Elecsys 2010 (Roche Diagnostics, Manheim, Germany) and analyzed 
correlations between the levels of NT-proBNP and echocardiographic parameters.
Results: NT-proBNP levels were higher in the patients with AR than AS (1517±657 
vs 748±647 pg/ml P<0.01) In AR , LVEDD (50±5 vs 62±10mm,, P<0.05) and LV mass 
(242±85 vs 292±108 gm, P<0.05) were signiﬁcantly increased than AS. In AS, the levels of 
NT-proBNP were correlated with LV mass (r=0.58, P<0.05) and mean aortic transvalvular 
pressure gradient (r=0.61, P<0.01) and peak PG (r=0.58, P<0.05), meanwhile in AR, LV 
and LA dimensions (r=0.37, P<0.05; r=0.51, p<0.05, respectively) and pulmonary artery 
pressure (r=0.88, p<0.01) were signiﬁcantly correlated with levels of NT-proBNP.
Conclusion: NT-proBNP levels were higher in AR than inAS, suggesting the volume-
overload is a stronger stimulus to release BNP from LV than the pressure-overload. 
Although LVEDD and LV mass, which reﬂect volume overload, increased in AR, these 
indexes were poorly correlated with the levels of NT-proBNP, LA dimension and pulmonary 
artery pressure, which represent LVEDP indirectly, were correlated with the levels of NT-
proBNP. In AS, NT-proBNP levels were signiﬁcantly correlated with LV mass and severity 
of stenosis.
1131-55 Gender Differences In Severe Aortic Stenosis
Padmini Varadarajan, Nikhil Kapoor, Ramesh C. Bansal, Ramdas G. Pai, Loma Linda 
University Medical Center, Loma Linda, CA
Background: Aortic stenosis (AS) is a common problem of the aging population 
with women having a higher surgical morbidity and mortality. We explored the gender 
differences in the responses to severe AS in terms of left ventricular function, anatomy, 
mitral valve function and pulmonary artery pressure.
Methods: Our echocardiographic database between 1993 and 2003 was screened for 
patients with severe AS deﬁned as a Doppler estimated aortic valve area (AVA) of <0.8 cm2. 
949 patients were identiﬁed forming the study cohort. Men and women were compared.
Results: Patient characteristics: age 74+13 years, 50% women, EF 54+20%, AVA 
0.74+0.4 cm2. Women and men were similar in age and transaortic mean gradients 
(42 mmHg). But women had a higher EF (57+20 vs 51+20%, p<0.0001) accompanied 
by a larger LV end-diastolic dimension index (29+5 vs 27+ 4 mm/m2, p<0.0001), but a 
similar end-systolic dimension index. Women also had a greater relative LV wall thickness 
(0.57+0.15 vs 0.53+0.14, p<0.0001) and LV wall thickness normalized for body size 
(p<0.0001) despite a similar LV mass index. They also had a greater preponderance of 
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3 or 4+ mitral regurgitation (27 vs 20%, p=0.007) and a higher pulmonary artery systolic 
pressure (48+16 vs 45+15 mmHg, p=0.02). Female gender was an independent predictor 
for the presence of 3-4+ mitral regurgitation.
Conclusions: 1) For similar aortic valve area and gradient, women with severe AS have 
a a higher EF and a greater relative and normalized LV wall thickness. 2) Female gender 
is also an independent predictor of 3-4+ mitral regurgitation unaccounted for by LV size 
and function.
1131-56 Mitral Regurgitation Worsens Post-Infarct LV 
Remodeling: Failure of Hypertrophic Compensation
Ronen Beeri, Chaim Yosefy, J. Luis Guerrero, Francesca Nesta, Susan Abeidat, 
Federica del Monte, Mark Handschumacher, Robert Stroud, Suzanne Sullivan, Thea 
Pugatsch, Dan Gilon, Gus J. Vlahakes, Francis G. Spinale, Roger J. Hajjar, Robert A. 
Levine, Masachusetts General Hospital, Boston, MA, Hadassah- Hebrew University 
Medical Center, Jerusalem, Israel
Mitral regurgitation (MR) doubles mortality following myocardial infarction (MI), but its 
additive effect on LV remodeling is debated and has not been addressed in a controlled 
fashion due to difﬁculties in standardizing and independently varying MI size and MR. We 
developed a model of apical MI (no intrinsic MR) with independent LV-to-LA MR-type ﬂow 
to address this question.
Methods: In 12 sheep, a standardized apical MI was created, and 6 had a Teﬂon shunt 
implanted between the LV and LA, consistently producing regurgitant fractions of ~30%. 
MR and sham sheep were compared at baseline, 1 and 3 months using 3D echo, Millar 
hemodynamics and biopsies.
Results: LV end-systolic volume progressively increased by 190% with MR vs 90% in 
sham (p<.02). LV dP/dt declined by 55±6% vs 15±22% (p<.01) with MR, with decreases in 
remote-zone sarcoplasmic reticulum Ca2+ ATPase levels (.56±.03 vs.76±.02, p<.001) and 
decrease in isolated cells contractility, which were more elongated. Akt, a pro-hypertrophic 
enzyme, was more up-regulated in the remote zones of MR sheep at 1 month, but was 
lower than shams at 3 months. The same pattern was observed for the receptor subunit 
gp130. Levels of caspase3, ﬁnal common pathway of apoptosis, were higher in all regions 
of MR hearts. Matrix metalloproteinase (MMP) 13, and membrane type MMP1 were 
increased in remote zones of MR vs sham animals, while tissue inhibitors of MMPs rose 
from baseline to follow-up and then to sacriﬁce in both border and remote zones of sham 
and MR animals, with signiﬁcantly higher levels at sacriﬁce in the MR group border zone. 
Six sheep with shunt closure after 1 month showed reversal of remodeling volume and 
dP/dt changes.
Conclusion: In this controlled model, moderate MR worsens post-MI remodeling, with 
larger LVs, reduced contractility and Ca2+ cycling proteins. While at ﬁrst pro-hypertrophic 
pathways are up-regulated, they subsequently fall below sham levels; along with sustained 
caspase3 elevation, transformation to a failure phenotype occurs. Extracellular matrix 
turnover also increases in MR animals. Therefore, MR can precipitate an earlier onset of 
dilated heart failure. Reversibility suggests potential clinical beneﬁt from eliminating MR.
POSTER SESSION
1159  Valve Disease, Surgery, and 
Endocarditis
Tuesday, March 08, 2005, 1:30 p.m.-5:00 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 3:30 p.m.-4:30 p.m.
1159-45 Tricuspid Valve Tethering Predicts Residual 
Regurgitation After Tricuspid Annuloplasty
Shota Fukuda, Jong-Min Song, A Marc Gillinov, Masao Daimon, Vorachai 
Kongsaerepong, Neil Greenberg, James D. Thomas, Takahiro Shiota, The Cleveland 
Clinic Foundation, Cleveland, OH
Background. Tricuspid valve (TV) annuloplasty is recommended for functional tricuspid 
regurgitation (TR), which is caused by TV annulus dilatation and tethering. However, the 
surgical outcome for functional TR is variable, and the impact of TV deformations on 
outcome of TV annuloplasty remains unknown.
Purpose. To investigate the relationship between preoperative TV deformation and 
residual TR after TV annuloplasty.
Methods. 216 patients with functional TR had 2-dimensional echocardiography before 
and after TV annuloplasty. The right ventricular (RV) fractional area change and left 
ventricular (LV) ejection fraction were determined using the apical views. Minimal 
TV annulus diameter was determined by frame by frame analysis. The distance of TV 
tethering was measured from TV annulus plane to the coaptation point and tethering area 
by tracing the TV leaﬂets from TV annulus plane during systole. The severity of TR was 
determined by the ratio of the maximal jet area to right atrial area. RV systolic pressure 
was calculated using the simpliﬁed Bernoulli equation. The impact of these preoperative 
parameters on residual TR severity after annuloplasty was assessed.
Results. Residual severe TR was observed in 7.4% patients and moderate TR in 15% 
after cardiac surgery. On univariate analysis, the severity of residual TR was associated 
with age (r=0.28, p<0.001), RV (r=0.18, p=0.01) and LV (r=0.19, p=0.005) dysfunction, 
tethering distance (r=0.56, p<0.001) and tethering area (r=0.52, p<0.001), and the severity 
of preoperative TR (r=0.32, p<0.001). TV annular dimension (p=0.3) and RV systolic 
pressure (p=0.8) were not associated with outcome of TV annuloplasty. Multivariate analysis 
revealed that age (p<0.001), tethering distance (p<0.001) and the severity of preoperative 
TR (p<0.001) were independent parameters, predicting residual TR. The sensitivity and 
speciﬁcity in predicting ≥moderate residual TR after surgery were 86% and 80% for tethering 
distance >0.76 cm, 82% and 84% for tethering area >1.63cm2, respectively.
Conclusions. Severe TV tethering predicted residual TR after TV annuloplasty, while 
preoperative TV annular dimension was not associated with outcome of TV annuloplasty.
1159-46 Severe Symptomatic Tricuspid Valve Regurgitation Due 
to Permanent Pacemaker Leads: Fact or Fiction?
Grace Lin, Rick Nishimura, Heidi Connolly, Joseph Dearani, Thoralf Sundt, David Hayes, 
Mayo Clinic, Rochester, MN
Background: The differential diagnosis of severe right heart failure usually involves 
pericardial, myocardial restrictive, or valvular heart disease. However, severe symptomatic 
tricuspid valve (TV) regurgitation caused by a permanent pacemaker (PPM) or implantable 
cardioverter deﬁbrillator (ICD) lead is an under-recognized but treatable entity.
Methods: We performed a retrospective chart review of 1465 consecutive patients (pt) 
who underwent TV repair or replacement at the Mayo Clinic between January 1, 1993 
and December 31, 2003. There were 157 pt who had prior PPM and, of these, 64 pt had 
severe TR conﬁrmed to be due to a PPM or ICD. Twenty-three pt were excluded because 
of associated cardiac trauma, congenital heart disease, endocarditis, or previous TV 
surgery. Forty-one pt met inclusion criteria and had severe TR conﬁrmed by pre-op 
transthoracic echocardiography (TTE) or transesophageal echocardiography (TEE).
Results: The mean age of these 41 pt was 70 years (20 men; 21 women). All 41 pt had 
a normal TV apparatus on operative inspection, and 14 had a dilated TV annulus. At 
operation, PPM lead related TV perforation was found in 7 pt, the PPM lead was entangled 
in the TV leaﬂets or chordae in 4 pt, impingement of the TV leaﬂets by the PPM lead was 
found in 16 pt, and adherence of the PPM lead to the valve was noted in 14 pt. When 
perforation occurred, the septal leaﬂet was most often involved (6/7). Valve perforation or 
impingement by a lead was suspected in only 5/41 pt by pre-op TTE ﬁndings and 4/13 pt 
by pre-op TEE. Fourteen of 38 pt had intra-op TEE ﬁndings suggestive of valve perforation 
or impingement prior to operative inspection. All pt underwent successful TV operation 
(22 TV replacement) with 1 peri-op death. Follow-up ranged from 1 to 99 months, during 
which 1 death from left-sided CHF occurred. There were 3 deaths from other causes. All 
surviving pt had improvement in signs and symptoms of right heart failure.
Conclusions: Damage or trauma to the TV by PPM leads may result in severe 
symptomatic TV regurgitation requiring TV operation and may not be overtly visualized by 
TTE or TEE. This etiology should be considered in pt presenting with severe right heart 
failure following PPM or ICD.
1159-47 What Patient Characteristics Lead to Contra-
indication of Surgery in Elderly Patients With Severe, 
Symptomatic, Aortic Stenosis ?
Bernard Iung, David Messika-Zeitoun, Gabriel Baron, Eric Brochet, Jean-Louis 
Vanoverschelde, Olaf W. Levang, Eric Boersma, Alec Vahanian, on behalf of the Euro 
Heart Survey on Valvular Heart Disease, Bichat Hospital, Paris, France
Background: Aortic stenosis (AS) is a frequent disease in the elderly, however, surgery 
raises speciﬁc problems, in particular because of the operative risk. Little is known regarding 
the factors leading to non-operation in the elderly. We used the data from the Euro Heart 
Survey on valvular heart disease, carried out in 2001, to identify the characteristics of 
elderly patients with severe, symptomatic, AS who were denied surgery.
Methods: Among the 5,001 pts included in the Euro Heart Survey, 1,197 had AS and 408 
of them were aged >= 75 years. Severe AS was deﬁned by a valve area >=0.6 cm²/m² body 
surface area or a mean gradient >=50 mm Hg. It was observed in 284 patients, among 
whom 216 had severe symptoms, i.e. NYHA class III or IV dyspnea and/or angina.
Of the 216 patients with severe, symptomatic AS, 124 were aged between 75 and 80, 58 
between 80 and 85, and 34 >= 85. Left ventricular ejection fraction (LVEF) was <50% in 
24% of patients. At least one comorbidity was present in 144 patients (67%). Either singly 
or in combination, 61% of patients had coronary artery disease, 18% previous myocardial 
infarction, 17% chronic obstructive pulmonary disease, 9% neurologic dysfunction, 6% 
carotid atherosclerosis, and 4% renal failure.
Results: Indication for surgery was considered in 144 patients (67%). In multivariate 
analysis, age (p=0.001), low LVEF (p=0.0005), and neurological dysfunction (p=0.03) 
were associated with the absence of operation, while this was not the case for the other 
comorbidities.
The Euroscore, which estimates the operative risk on the basis of 17 variables, was 
signiﬁcantly higher in non-operated patients than in operated patients (9.4±2.9 vs. 
8.1±1.8, p<0.001). When adding the Euroscore in the model, older age (p=0.02) and 
lower LVEF (p=0.01) continued to be associated with the absence of operation, while a 
higher Euroscore did not have a signiﬁcant impact (p=0.25).
Conclusion: In this population of elderly patients with severe, symptomatic AS: 1) 
Surgery was denied in as many as 33% of cases. 2) Older age and depressed LVEF were 
the characteristics most strongly associated with the absence of surgery, even more than 
a global estimation of the operative risk using the Euroscore.
1159-48 Changing Pattern of Infective Endocarditis: A 
Population Study at Olmsted County, Minnesota
Imad M. Tleyjeh, Hani S. Murad, Hassan M. Ghomrawi, Sherif E. Moustafa, Zaur 
Mirzoyev, Nandan S. Anavekar, James M. Steckelberg, Barbara P. Yawn, Larry M. 
Baddour, Mayo Clinic College of Medicine, Rochester, MN, University of Minnesota, 
School of Public Health, Minneapolis, MN
Background: Limited data exist that examine population-based epidemiological changes 
in infective endocarditis (IE). The goal of this study was to determine whether there is a 
changing spectrum of IE in a population-based cohort
Methods: The study cohort included all adult patients with IE in Olmsted County, MN 
from January 1970 to December 2000 identiﬁed by The Rochester Epidemiology Linkage 
System. This population consists largely of middle-class whites, with an extremely low 
prevalence of intravenous drug abuse.Cases were deﬁned according to the modiﬁed 
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Duke criteria (criteria applied retrospectively for cases before 1996). Clinical data were 
extracted from medical records. The incidence rate of IE was calculated assuming 
that the entire population of Olmsted County was at risk of IE and using the decennial 
census ﬁgures. Incidence rates were adjusted for age and sex in Olmsted County. 95 % 
conﬁdence intervals were estimated from a Poisson distribution.
Trends in the incidence and characteristics of IE were analyzed over the 30-year period.
Results: 
Time trend analysis for changing infective endocarditis characteristics at  
Olmsted County, MN 
Characteristic /(Age and Sex 
Adjusted Incidence rate/1000,000 
person-years)
1970-74
(N=15)
1975-79
(N=18)
1980-84
(N=20)
1985-89
(N=22)
1990-94
(N=25)
1995-00
(N=32)
Age, mean (SD) y 57.15 (22.01)
56.14 
(23.22)
56.55( 
21.64)
58.58 
(18.54)
59.48 
(16.68)
66.11 
(15.62)
Sex, Female No. (%) 3 (20%) 6 (33.3%) 8 (40%) 8 (27.3%) 8 (32%) 6 (25%)
Adjusted Incidence rate/1000,000 
person-years [95% CI] 58[29,88] 52[28,76] 61[3,88] 62[4,88] 65[39,90] 62[41,84]
Underlying Cardiac Disease
Rheumatic Heart Dis [95% CI] 15[0,3] 24[7,40] 21[5,37] 17[3,30] 13[2,24] 10[1,18]
Mitral Valve Prolapse [95% CI] 4[0,12] 27[0,79] 6[0,15] 23[7,38] 21[6,35] 8[0,15]
Congenital Heart Dis [95% CI] 8[0,19] 8[0,18] 12[0,25] 3[0,9] 3[0,8] 2[0,6]
Bicuspid Aortic Valve [95% CI] 0 12[0,23] 3[0,87] 14[2,27] 3[0,8] 0
Organism 
Viridans Streptococcus [95% CI] 24[5,43] 17[3,31] 22[6,38] 28[11,46] 18[5,32] 31[16,47]
Staphylococcus Aureus [95% CI] 11[0,25] 12[0,24] 18[4,33] 14[2,26] 23[8,39] 14[4,24]
Enterococcus [95% CI] 8[0,18] 0 0 3[0,8] 5[0,12] 4[0,9]
Other Streptococcus [95% CI] 4[0,10] 6[0,14] 6[0,14] 3[0,9] 5[0,12] 4[0,9]
Coagulase-negative 
Staphylococcus [95% CI] 0 0 12[0,24] 9[0,18] 3[0,8] 0
Valves Involved 
Native Total [95% CI] 54[26,83] 43[21,65] 43[2,66] 47[25,72] 44[23,65] 51[31,70]
Prosthetic Total [95% CI] 4[0,12] 9[0,18] 18[4,33] 14[2,26] 21[6,35] 12[2,21]
Valve surgery [95% CI] 0 9[0,19] 19[4,33] 17[3,31] 13[2,24] 23[10,37]
Conclusion: The incidence of IE in the population of Olmsted County has remained 
relatively unchanged over the 30 years period of our study. In addition, the leading 
causative organism remains to be Viridans Streptococci, and not Staphylococcus aureus, 
to the contrary of most recent reports from tertiary care centers.
1159-55 The Use and Effect of Surgical Therapy for Prosthetic 
Valve Infective Endocarditis: A Propensity Analysis of a 
Multicenter, International Cohort
Andrew Wang, Paul Pappas, Kevin J. Anstrom, Elias Abrutyn, Vance G. Fowler, Bruno 
Hoen, Jose M. Miro, G. Ralph Corey, Lars Olaison, Judith A. Stafford, Carlos A. Mestres, 
Christopher H. Cabell, and the International Collaboration on Endocarditis (ICE) 
Investigators, Duke University Medical Center, Durham, NC
Background: Surgical therapy is commonly recommended for patients with prosthetic 
valve endocarditis (PVE). However, the effect of surgery for PVE has not been well 
deﬁned, particularly in light of differing characteristics of patients treated with surgery 
versus medical therapy alone.
Methods: The International Collaboration on Endocarditis (ICE) Merged Database was 
used to evaluate the application and outcome of surgery for PVE. Clinical, microbiologic, 
and echocardiographic differences between PVE patients treated with surgical therapy 
(in conjunction with medical therapy) and those treated with medical therapy alone were 
determined. Propensity scores were created based on those factors favoring the use of 
surgery for PVE. Using these propensity scores, patients who underwent surgery were 
matched with patients treated with medical therapy alone. Logistic regression analysis 
was then performed to determine those factors predictive of in-hospital mortality.
Results: Deﬁnite PVE by Duke criteria was present in 355 patients; surgical treatment 
was utilized in 148 (41.6%) patients (median time to surgery =12.0 days) and 207 (59.4%) 
patients were treated medically. The in-hospital mortality rate was 24.3% for patients 
treated with surgery compared to 22.7% treated with medical therapy alone (p=0.729). 
Surgical treatment was predicted by the presence of intracardiac abscess, heart failure, 
coagulase negative Staphylococcal and S. aureus infection, mitral valve vegetation, age, 
and year of diagnosis (area under ROC=0.829). Using the matched propensity sample 
of 136 patients with PVE, in-hospital mortality was predicted by cerebrovascular embolic 
event (OR 11.12, 95% CI 4.16-29.73) and S. aureus infection (OR 3.67, 95% CI 1.39-
9.74), with a trend toward a survival beneﬁt for surgical treatment (OR 0.56, 95% CI 
0.23-1.35) (area under ROC=0.797).
Conclusions: Among patients with PVE, in-hospital mortality is strongly related to S. 
aureus infection and the occurrence of cerebrovascular embolic event, with an overall 
trend toward survival beneﬁt from surgery. Surgery for complicated PVE results in a 
similar in-hospital survival rate as uncomplicated PVE treated without surgery.
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Orange County Convention Center, Room 230D
2:00 p.m.
853-3 Heart Failure Complicating Mitral Regurgitation: 
Determinant Impact Of The Effective Regurgitant Oriﬁce
Maurice Enriquez-Sarano, David Messika-Zeitoun, Delphine Detaint, Maryann Capps, 
Christopher Scott, Jamil Tajik, Mayo Clinic, Rochester, MN
Background: Mitral regurgitation (MR) is frequent and may be associated with poor 
outcome. Clinical guidelines recommend quantitative assessment of MR but the impact of 
the effective regurgitant oriﬁce (ERO) and regurgitant volume (RVol) on clinical outcome, 
particularly the occurrence of heart failure (CHF) after diagnosis is unknown.
Methods: In a prospective study, 566 patients (64±14 years, 62% males) with MR due 
organic disease of the mitral valve underwent quantitation of MR by at least 2 methods 
and of left ventricular (LV) function. After completion of the enrollment, clinical outcome 
was measured as the occurrence of CHF after diagnosis and under conservative 
management.
Results: At baseline ERO was 44±30 mm2, RVol 68±42 mL/beat, Ejection fraction 
69±9% and end-systolic volume index 34±14 mL/m2. During follow-up under 
conservative management 2.5±2.9 years, 76 episodes of CHF occurred, due to the MR 
in 64, representing 5.4% patients year or a 10-year rate of 40±6%. Both ERO and RVol 
were univariate predictors of subsequent CHF but ERO conveyed the entire predictive 
value related to the degree of MR (p<0.001). In multivariate analysis, ERO remained 
a determinant of CHF independently of age, gender, baseline symptoms and ejection 
fraction (RR 1.02 [1.01-1.03] per mm2, p<0.0001). The 7-year and yearly linearized rates 
of CHF were 17±5% and 2.4%/year for ERO<20 mm2, 29±6% and 5.5%/year for ERO 
20-39 mm2 and 65±11% and 15%/year for ERO ≥40 mm2. Compared to patients with 
ERO<20 mm2, the adjusted RR of CHF was 2.66 [1.29-5.6] for patients with ERO 20-30 
mm2 and 5.5 [2.64-11.9] for ERO ≥40 mm2.
Conclusions: In patients with MR due to organic valve disease, CHF is a frequent 
complication under conservative management. The baseline quantitative classiﬁcation 
of MR has important outcome implications independent of all other characteristics. 
In patients with large ERO (≥40 mm2) the high rates of CHF suggest that aggressive 
therapeutic strategies should be tested to improve clinical outcome.
2:15 p.m.
853-4 Surgery for Severe but Asymptomatic Mitral 
Regurgitation?
Raphael Rosenhek, Florian Rader, Harald Gabriel, Christine Scholten, Maria Heger, 
Ursula Klaar, Marcel Krejc, Daniel Kalbeck, Gerald Maurer, Helmut Baumgartner, 
Medical University Vienna, Vienna, Austria
Background: The management of severe but asymptomatic organic (degenerative) 
mitral regurgitation (MR) remains controversial. The aim of this study was to evaluate 
a relatively conservative strategy referring patients to surgery when symptoms occur 
or when asymptomatic patients develop left ventricular (LV) enlargement (endsystolic 
diameter ≥ 45 mm), impairment of LV-function (EF < 60%), pulmonary hypertension (PHT, 
systolic pressure > 50 mmHg) and/or new onset atrial ﬁbrillation.
Methods: 132 consecutive asymptomatic patients (age 55±15 yrs, 49 female) with severe 
degenerative MR who were referred to our outpatient clinic between 1995 and 2002, were 
prospectively followed until July 2004 (mean follow-up 62±26 months). Patients underwent 
serial clinical and echocardiographic examinations and were referred to surgery when the 
criteria mentioned above were fulﬁlled.
Results: 32 patients eventually underwent mitral valve surgery. Reason for surgery 
was development of symptoms (21), LV-criteria (10), PHT (10), atrial ﬁbrillation (7). 15 
patients fulﬁlled more than 1 criterion. 4 pts died before surgery (1 sudden death in an 
80 year-old man, 3 unrelated to MR). 2 deaths occurred in patients who had refused 
surgery (1 unknown, 1 cancer). There was no operative mortality. Postoperative outcome 
was good with regard to survival (no MR-related deaths, 2 deaths following stroke and 
myocardial infarction, respectively) and symptomatic status (NYHA functional class I in 
24 pts, class II in 8 pts). At last follow-up, left ventricular function was normal in 28 of 32 
patients. 4 pts with LV-dysfunction had either additional bypass-surgery or required mitral 
valve replacement (repair unsuccessful). Overall survival for the entire patient group was 
99±1% at 2 yrs, 96±2% at 4, 91±3% at 6 and 91±3% at 8 yrs.
Conclusion: Asymptomatic patients with severe organic mitral regurgitation can be safely 
followed until either symptoms occur or currently recommended cutoff values for LV size, 
LV function or PHT are reached. This management strategy is associated with good peri- 
and postoperative outcome but requires careful follow-up with serial echocardiographic 
examinations.
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853-5 Degenerative versus Rheumatic Mitral Valve Disease: 
Evaluation of Cellular Proliferation and Osteoblast 
Mediated Extracellular Matrix Production
Sanjay Pandya, Malayannan Subramaniam, Stuart Stock, Thomas Spelsberg, Patrick 
McCarthy, Robert Bonow, Nalini Rajamannan, Northwestern University, Chicago, IL, 
Mayo Clinic, Rochester, MN
Introduction: Mitral valve disease due to degeneration causing mitral regurgitation, and 
rheumatic fever causing stenosis, are common forms of mitral valve disease. The cellular 
mechanisms are not well known. We have previously reported osteoblast expression in 
rheumatic calciﬁed valves(ACC2004) and hypothesize a similar mechanism for mitral 
valve degeneration. 
Methods: Degenerative mitral valves (N=20), rheumatic mitral valves (N=23) and controls 
(N=20) were studied. Electron microscopy (EM) was performed. Immunohistochemistry 
was used to localize osteopontin, alpha actin, proliferating cell nuclear antigen(PCNA) 
and CD68. MicroCT and Alizarin red(AR) demonstrated the amount of calciﬁcation. A 
4-point grading system was used to visually describe the staining on each of the slides 
(1=no staining, 4=high staining). 
Results: Table 1 demonstrates the results. 
Conclusions:These ﬁndings support the evidence that cellular proliferation and matrix 
production are important in the development of mitral valve disease. The severity of 
calciﬁcation correlates with the higher level of cellular proliferation and matrix production 
in the calciﬁed rheumatic valves as compared to degenerative mitral valves. These 
conclusions provide the foundation for our understanding of the cellular processes 
important in the varying clinical presentations of mitral valve disease.
Table 1 
Actin PCNA OPN CD 68 AR EM MicroCT
Degenerative 1.5+/-0.57 2.25+/-1.25 2.25+-/1.25 1.25+/-0.5 3+/-1.41 1+ 1+
Rheumatic 3+/-0.25 4+/-0.25 4+/-0.25 4+/-0.25 4+/-0.25 3+ 4+
Control 1+/-0 1+/-0 1.5+/-0 1+/-0 1+/-0 1+ 0
2:45 p.m.
853-6 Signiﬁcance of Atrial Fibrillation Before Mitral Valve 
Repair For Degenerative Mitral Regurgitation: A 
Propensity Case-Match Analysis
Kosei Eguchi, Eiji Ohtaki, Takayoshi Matsumura, Kaoru Tanaka, Tetsuya Sumiyoshi, 
Hitoshi Kasegawa, Saichi Hosoda, Sakakibara Heart Institute, Tokyo, Japan, Ohtaki 
Cardiology Clinic, Tokyo, Japan
Background: Recent studies on the outcome of mitral valve (MV) repair included patients 
with ischemic mitral regurgitation (MR) and did not demonstrate independent signiﬁcance 
of atrial ﬁbrillation (AF) on survival.
Methods: Among 392 patients with moderate to severe MR who underwent MV repair 
between 1991 and 2002, 283 patients(SR 54%) with isolated degenerative MR were 
followed for 4.8±3.3 years. Follow up rate until 2002 was 100%. In addition to analysis 
on whole population, propensity analysis with greedy matching technique was used to 
construct matched cohorts of patients with preoperative SR(n=48) and AF(n=48).The 
maximum allowable difference for matching was < 0.1 in the propensity score. Preoperative 
age, sex, NYHA, history of hospitalization due to heart failure, left ventricular (LV) ejection 
fraction, LV end-systolic diameter, LV end-diastolic diameter, left atrial diameter, and right 
ventricular systolic pressure are included in the statistical analysis.
Results: In patients with preoperative SR compared with those with preoperative AF, 
survival was higher(88±6% versus 74±6% at 10 years, p=0.002), cardiac event-free rate 
was also higher(78±8% versus 57±6% at 10 years, p<0.001). Cox multivariate regression 
analysis conﬁrmed AF [p=0.027, adjusted hazard ratio(HR) 2.8] and age as independently 
predictive of survival, and AF [p=0.005, adjusted HR 2.9], NYHA, and LV ejection fraction 
as independently predictive of cardiac event-free rate. Even in the propensity case-match 
analysis, preoperative AF was associated with a trend of worse survival[p=0.231, HR=2.6] 
and signiﬁcant worse cardiac event-free rate[p=0.039, HR=3.7]. Only 3 out of 27 deaths 
were due to LV dysfunction. Nine deaths were due to cardioembolic events. Postoperative 
LV ejection fraction was 61±12% and postoperative LV dysfunction (deﬁned as LV ejection 
fraction < 50%) was not frequent (17.6%).
Conclusion: Successful preservation of LV function by MV repair has made the 
cardioembolic events due to AF the leading cause of cardiac mortality and morbidity. As a 
result, independent signiﬁcance of AF before MV repair was demonstrated with both Cox 
multivariate analysis and propensity case-match analysis.
3:00 p.m.
853-7 Ischemic Mitral Regurgitation With Segmental Anterior 
Myocardial Infarction: New Mechanistic Insights With 
Potential Therapeutic Implications
Chaim Yosefy, Ronen Beeri, Luis J. Guerrero, Mark D. Handschumacher, Robert A. 
Levine, Massachusetts General Hospital,Harvard Medical School, Boston, MA
Ischemic mitral regurgitation (IMR) accompanies inferior or global left ventricular (LV) 
remodeling, with leaﬂet tethering by displaced papillary muscles (PMs). IMR is also 
reported with segmental anterior myocardial infarction (MI) without global dilatation. 
Based on clinical observations, we tested the hypothesis that anterior MI extension to 
the inferior apex can mechanically displace PMs and in turn tether the mitral leaﬂets to 
cause MR.
Methods. Echo database was searched over 3 years for patients (pts) with isolated 
anteroapical MIs (not inferoposterior or lateral base or mid-LV) with EF > 40%, involving 
2 anterior or all 4 apical segments. Mechanistic studies compared 20 pts with apical MI 
(4 segments) and moderate MR; 20 with apical MI (2 segments) and trace MR; and 20 
normals for LV and mitral dimensions.
Results. Moderate-severe MR occurred in 9% of 234 pts with only anteroapical MI (EF = 
46%) vs 17% of 242 with inferoapical extension (EF = 41%; P < .001). In the mechanistic 
study, inferoapical bulging restrained the posterior PM apically; MR grade correlated most 
strongly with the systolic PM-to-annulus tethering length (TL; r=.75) and its diminished 
systolic shortening (r=-.60); in multiple regression, these contributed r2 = .63 of .75 total. The 
mechanism was reproduced in 4 sheep with anterior MI extending to the inferior apex.
Conclusions. Anterior MI with inferoapical extension can mechanically displace 
nonischemic PMs, causing IMR. This mechanism suggests potential for mechanical repair.
 
3:15 p.m.
853-8 Exercise Tolerance but Not ST Segment Response to 
Exercise Predicts Event-Free Survival In Asymptomatic 
Chronic Nonischemic Mitral Regurgitation
Phyllis Gail Supino, Jeffrey Stephen Borer, Karlheinz Schuleri, Clare Hochreiter, Anuj 
Gupta, Paul Kligﬁeld, Edmund McMahan Herrold, Mayan Bomsztyk, Weill Medical 
College of Cornell University, New York, NY
Background: In many forms of heart disease, including aortic regurgitation, the 
exercise ECG has useful functional correlates and prognostic value but there are few 
data regarding its predictive value in patients (pts) with nonischemic mitral regurgitation. 
Methods: We prospectively evaluated 38 asymptomatic pts (avg age: 50±12 years; 68% 
male) with chronic severe nonischemic mitral regurgitation to determine whether exercise 
duration or ST segment depression (≥ 1 mm additional horizontal or downsloping) during 
a modiﬁed Bruce exercise treadmill protocol (including an initial 3 min at grade 00, 1.7 
mph) predict clinical outcome or currently accepted indications for mitral valve surgery. 
At study entry, all pts had normal systolic function at rest (LV ejection fraction [EF] ≥60% 
by echocardiography, RVEF≥ 35% by radionuclide cineangiography, LV dimensions at 
systole (IDs) ≤ 4.5 cm) and were free of atrial ﬁbrillation (AF) and congestive symptoms; 
6 pts were on digoxin. Avg event-free followup was 6±5 years. 
Results: Events during follow-up included: sudden cardiac death (n=1), LVIDs>4.5 
cm (n=11), LVEF<60% (n=3), RVEF<35% (n=1), LVEF<60% + LVIDs>4.5 cm (n=2), 
RVEF<35% + LVIDs>4.5 cm (n=1), AF (n=3), congestive symptoms ± RVEF<35% ± 
LVIDs>4.5cm (n=4). Avg annual cardiac event risk (AAR) was 15.3% among all pts; it 
was 3-fold lower among pts with exercise duration ≥ 15 minutes (highest tercile of the 
distribution of exercise duration, AAR=6.8%) than in pts with exercise duration <15 
minutes (AAR=22.2%, p<.02; p<.02 [age/gender adjusted]). In contrast, event rates in pts 
without and with ST segment depression were statistically indistinguishable among all pts 
(AAR=13.2% [without] vs. 17.6% [with], p>.10 [NS]) and in the subgroup of 32 pts not on 
digoxin at study entry (AAR=13.2% [without] vs. 14.5% [with], p>.10 [NS]). 
Conclusions: Among asymptomatic pts with chronic severe nonischemic mitral 
regurgitation, progression to current indications for mitral valve surgery generally is rapid, 
suggesting need for frequent assessment. However, the subgroup of pts with excellent 
exercise tolerance has a relatively benign course. ST segment depression has no 
prognostic value in this population.
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Orange County Convention Center, Room 232A
8:30 a.m.
873-3 Coapsys Mitral Valve Repair Improves 1 Year Outcomes 
in Patients with Ischemic Mitral Regurgitation 
Undergoing Off-Pump CABG
Sanjay Mittal, Yugal Mishra, Pravesh Jaguri, Naresh Trehan, Escorts Heart Institute and 
Research Centre, New Delhi, India
Background: Untreated functional ischemic mitral regurgitation (IMR) leads to reduced 
survival in patients with coronary artery disease. However, mitral valve (MV) repair or 
replacement for IMR increases mortality and morbidity over coronary artery bypass 
grafting (CABG) alone. Our institution has been treating IMR patients using the Coapsys, 
a novel device that is implanted on a beating heart without atriotomy. 
Methods: 23 patients referred for CABG with grade 2 or greater IMR were included in 
the analysis. Patients with intraoperative regression of MR to grade 1 or less, despite 
hemodynamic challenge, served as an Untreated comparison to patients with persistent 
intraoperative MR who were implanted with the Coapsys. Clinical and echo follow-up data 
was collected at 12 months. 
Results: 13 patients were treated with Coapsys with 10 were left Untreated. Baseline 
age, ejection fraction, mean number of grafts, MR grade, MR jet area, MV tenting area 
and NYHA classiﬁcation were not different between groups. Intraoperative MR grade was 
different between the Coapsys (2.9 ± 0.5) and Untreated (0.9 ± 0.6) groups. Follow-up 
data is in Table 1 (* p<0.05 vs. Baseline).
Table 1 
Coapsys
Baseline
Coapsys
1 Year
Untreated 
Baseline
Untreated
1 Year
Coapsys vs. Untreated
(p-Value @ 1 Year)
MR Grade 3.00±0.55 1.15±0.99* 2.70±0.82 2.00±0.82 0.04
MR Jet Area (cm2) 7.7±3.7 2.9±2.2* 6.5±2.7 5.6±1.9 0.01
MV Tenting Area (cm2) 3.7±1.1 2.3±0.7* 3.9±1.2 3.1±0.9 0.02
NYHA Classiﬁcation 2.7±0.5 1.2±0.4* 2.5±0.5 1.7±0.5* 0.02
Conclusions: Coapsys is effective in signiﬁcantly reducing IMR and improving 
NYHA classiﬁcation at 1 year. Furthermore, Coapsys treated patients demonstrate 
signiﬁcant reduction in MR indices, which were sustained at 1 year follow up along with 
improvement of NYHA class as compared to similar Untreated patients who downgraded 
intraoperatively.
8:45 a.m.
873-4 The Effect of Tricuspid Valve Surgery on Right 
Ventricular Function in Patients With Functional 
Tricuspid Regurgitation
Shota Fukuda, A Marc Gillinov, Jong-Min Song, Masao Daimon, Vorachai 
Kongsaerepong, Takashi Kihara, Neil Greenberg, James D. Thomas, Takahiro Shiota, 
The Cleveland Clinic Foundation, Cleveland, OH
Background. The effect of tricuspid valve (TV) surgery on right ventricular (RV) function 
is unknown, and the speciﬁc impact of different surgical approaches has not been 
investigated.
Purpose. To investigate changes in RV function in patients with functional TR after 3 
different managements strategies.
Methods. 229 patients with functional TR undergoing left-sided cardiac surgery were 
studied by 2-dimensional echocardiography before and after surgery. The patients were 
divided into 3 groups; no surgery on TV (only left-sided surgery, non TV surgery group, 
n=41), TV annuloplasty with left sided surgery (n=174), and TV replacement (TVR) with 
left sided surgery (n=14). Left ventricular (LV) volume and ejection fraction (EF) were 
determined with the Simpson method. RV diastolic and systolic areas, and fractional area 
change (FAC) were obtained from the apical 4-chamber view. The severity of TR was 
determined by the ratio of the maximal jet area to the right atrial area. These parameters 
were obtained before and after surgery, and percent change in each parameter was 
calculated.
Results. Decrease in TR after surgery in non TV surgery group (-7.2±58.2%) was smaller 
than those of annuloplasty (-66.7±33.7%) and TVR groups (-92.1±11.7%) (p<0.001 vs 
non TV surgery group, respectively). The TVR group had a greater decrease in TR than 
the annuloplasty group (p<0.001). There were no signiﬁcant differences among the 3 
groups in changes of LV volume and LV EF (p=NS). In contrast, diastolic and systolic RV 
areas were markedly diminished after TVR (-29.6±17.9% and -15.0±27.2%), while those 
in non TV surgery group (9.6±26.2% and -2.6±27.6%) and annuloplasty (-0.9±31.7% 
and 3.1±33.2%) was unchanged or slightly increased. However, the TVR group showed 
declined RV FAC (-22.2±53.2%), while RV FAC was improved in annuloplasty (6.6±71.1%) 
and non TV surgery groups (32.1±63.8%, p<0.05 vs other 2 groups).
Conclusions. TVR provided more complete elimination of TR than annuloplasty. 
However, RV function was reduced after TVR while it was preserved after annuloplasty. 
This suggests that improved techniques of TV annuloplasty are necessary in order to 
achieve optimal reduction of TR while preserving RV function.
9:00 a.m.
873-5 What is the Current Operative Risk of Aortic Valve 
Surgery for Asymptomatic Aortic Valve Disease
Prem S. Shekar, Sary F. Aranki, Gregory S. Couper, Marzia Leacche, Margaretta Taft, 
Lawrence H. Cohn, Brigham and Women’s Hospital, Boston, MA
Background: Asymptomatic aortic valve disease is increasingly recognized as echocardiography 
increases case yield. This study evaluates the risk of surgery in “asymptomatic” patients who 
underwent aortic valve replacement (AVR) over a 12 year period.
Methods: Between 1992-2004, 240 consecutive asymptomatic or mildly symptomatic 
patients New York Heart Assocation Functional Class I (NYHA FC) underwent AVR for 
aortic stenosis (AS) or aortic regurgitation (AR) with or without coronary artery bypass 
grafting(CABG). The mean age for AS (N=196) was 70 years (31-91) and the mean age 
for AR (N=44) was 54 (30-84); 75% were males. All patients were operated upon with 
the use of cardiopulmonary bypass, moderate hypothermia and cold blood cardioplegia; 
115 had bioprosthetic valves, 103 had prosthetic heart valves, 17 had homograft root 
replacement and 5 had valve repair. Patients with reoperations or other concomitant 
cardiac operations except CABG were excluded.
Results: The overall mortality for NYHA FC I was 2/240 (0.8%). In 149 patients > 65 
years the operative mortality was 1/149 (0.6%). the 2 mortalities were from arrhythmias. 
The table below indicates the operative risk per lesion with or without CABG.
Isolated With CABG
AS 0/35 (0%) 0/9 (0%)
AR 0/82 (0%) 2/114 (1.8%)
Total 0/117 (0%) 2/123 (1.6%)
Conclusion: Asymptomatic or mildly symptomatic AS or AR with or without CABG is 
associated with a very low perioperative morbidity and mortality. Earlier consideration for 
operation should be given to patients with “asymptomatic” aortic valve disease, especially 
elderly patients.
9:15 a.m.
873-6 Short-Term Outcomes of Atrial Fibrillation Complicating 
Coronary Artery Bypass Graft Surgery: Results From 
the PREVENT-IV Trial
Sana M. Al-Khatib, Abhinav Goyal, Gail E. Haﬂey, John H. Alexander, Michael J. Mack, 
Randall K. Wolf, Lawrence H. Cohn, Daniel Gennevois, Robert A. Harrington, Eric D. 
Peterson, Kerry L. Lee, Robert M. Califf, Nicholas T. Kouchoukos, T. Bruce Ferguson, Jr., 
for the PREVENT-IV Investigators, Duke University Medical Center, Durham, NC
Background: Although some have suggested that atrial ﬁbrillation (AF) complicating 
coronary artery bypass graft surgery (CABG) is associated with a higher risk of death, 
evidence to date has been conﬂicting.
Methods: We examined the incidence and outcomes of AF in the 2,795 patients with 
cardiac rhythm data enrolled in the PREVENT-IV study, an ongoing randomized comparison 
of edifoligide (an E2F transcription factor inhibitor) versus placebo administered during 
CABG for the long-term prevention of saphenous vein graft failure. We compared baseline 
characteristics and outcomes (death, myocardial infarction, and stroke) from hospital 
discharge to 30 days in patients with (n=673) and without (n=2,122) in-hospital post-
CABG AF. We also examined the effect of AF on length of stay in the intensive care unit 
(ICU) and on length of hospitalization.
Results: The incidence of post-CABG AF was 24%. The median time to AF following 
CABG was 50 hours (interquartile range 37 to 70 hours). The table presents signiﬁcant 
differences in baseline characteristics and in outcomes between the two groups.
Conclusion: Patients with AF are older and have more comorbidities than those 
without AF. Post-CABG AF is associated with a higher risk of 30-day death, longer 
ICU stay, and longer hospitalization. In order to optimize outcomes in patients 
undergoing CABG, future studies should seek to identify patients at highest risk 
for AF and explore methods of preventing and treating post-CABG atrial ﬁbrillation. 
 
Baseline Characteristics and Outcomes by  
Post-CABG Atrial Fibrillation Status 
BASELINE VARIABLES Post-CABG AF No post-CABG AF P-value
Age (years; median, IQR*) 67 (61,73) 61 (54,69) < 0.01
Caucasian race (%) 94.2 89.2 < 0.01
Hypertension (%) 77.4 73.8 0.06
Chronic lung disease (%) 19.6 13.8 < 0.01
Cancer (%) 11.7 7.0 < 0.01
NYHA class III or IV (%) 30.1 15.1 0.06
Preoperative ejection fraction (%; median, IQR) 50 (42, 60) 50 (41, 60) 0.87
OUTCOMES
Length of ICU stay (hours; median, IQR) 28 (22, 54) 25 (22, 44) <0.0001
Length of hospitalization (days; median, IQR) 8 (6, 11) 7 (6, 9) <0.0001
30-day death (%) 1.6 0.7 0.03
30-day myocardial infarction (%) 0.6 0.5 0.81
30-day stroke (%) 0.6 0.2 0.15
* IQR = interquartile range
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9:30 a.m.
873-7 Three Dimensional Ring Annuloplasty: A Signiﬁcant 
Advance For The Treatment Of Tricuspid Regurgitation
Farzan Filsouﬁ, Sacha P. Salzberg, Kai TJ von Harbou, Lishan Aklog, Martin E. 
Goldman, David H. Adams, Mount Sinai Medical Center, New Yrok, NY
Background: Functional tricuspid regurgitation (FTR) should be corrected in patients 
with left sided valve disease in order to improve long-term outcome. The Edwards MC3 
remodeling ring accommodates the 3D saddle shape of the tricuspid annulus, which may 
further improve the stability of the repair over time. Herein we report our early clinical 
results.
Material: From 1/03 to 8/04, 52 Patients (22M/30F, mean age 63y(31-92), EF 49(10-
60), NYHA 3(2-4)) underwent tricuspid valve repair (TVR) for FTR (grade ≥3) due to 
annular dilatation with the Edwards MC3 system. Etiology of left sided valvular disease 
was: rheumatic (n=21), degenerative (n=16), ischemic CMP (n=6), endocarditis (n=5), 
congenital (n=3), and lupus (n=1). 16 Patients underwent redo operations. Concomitant 
procedures: MV surgery (repair n=34, replacement n=13), aortic valve replacement (n=5), 
CABG (n=6) and LA maze (n=14).
Results: Operative and late mortality were 3.8%(n=2) and 7.2%(n=4) respectively. 
Echocardiography at discharge showed a mean TR decreased to 1.1 (p<0.001) and MR 
to 0.4 (p<0.001) while EF increased to 53% (p=0.047), and at 6 Month follow-up, TR and 
MR were 1.5(0-2) and 0.8(0-2) respectively, while EF was 52%(20-60).
Conclusion: Concomitant tricuspid valve repair for FTR associated with left sided 
valve surgery carries low operative mortality. Prior studies have shown higher residual/
recurrent TR utilizing non speciﬁc rings or suture techniques. These results suggest three 
dimensional rings represent a signiﬁcant advance in the treatment of TR.
9:45 a.m.
873-8 Towards 100% Repairability of Mitral Insufﬁciency: Role 
of Complex Repair Techniques
Gerald M. Lawrie, Elizabeth Ann Earle, Nan R. Earle, The Methodist DeBakey Heart 
Center, Houston, TX
Background: Most insufﬁcient valves can be repaired by the application of a single repair 
technique (RT). However, in some cases the repair of both leaﬂets or the use of two or 
more RTs in addition to annuloplasty is required for a complete repair. The durability of 
complex RTs (CRT) is not well documented and valve replacement has been suggested 
as a preferable alternative.
Methods: We compared the outcome of simple repair (SRT) vs. (CRT) in 547 consecutive 
pts. on a single service operated on from 1983-2003 for mitral regurgitation. Median age 
was 65 (range 16-93), males, 50.6% (p=NS for complex repair vs. simple repair for both.) 
Preoperative EF: 55% (range 15-88), but simple repair was 55% (15-85) vs. complex 
repair, 60% (20-88), (p=0.0017). Techniques included leaﬂet resection/plication, PTFE, 
chordal replacement, and pericardial patch grafts along with ring annuloplasty and Kay 
annuloplasty. Complex repair was done in 148 pts (27.1%). Bileaﬂet repair was done in 
57 pts, (10.4%).
Results: Perioperative mortality for complex repair was 2.7% (4/148) and for simple repair, 
3.8% (5/399), (p=NS). Hospital length of stay was 9.0 days (range 0-111) for complex 
repair and 9 days (range 0-141) for simple repair (p=NS). Kaplan-Meier estimates of 
survival at 5 and 10 years were for complex repair: 5 years, 86%; 10 years, 64%; and for 
simple repair: 5 years, 70%; 10 years, 47.9% (p=0.383). Freedom from reoperation at 5-10 
years for complex repair: 5 years, 87.1%; 10 years, 81.9%; and for simple repair: 5 years, 
76.3%; 10 years, 76.3% (p=NS).
Conclusion: Complex repair produced good long-term results, which were as good as 
simple repair. These data suggest that insufﬁcient valves should be repaired by applying 
additional techniques if simple repair does not abolish all mitral regurgitation. The long-
term reliability of CRT exceeded that of SRT in this study and complete correction 
appeared to enhance long-term survival in these patients.
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